## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-02-03_Virtual Town Hall 41_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/145756/download?attachment
link youtube: https://youtu.be/SkNByAteggE
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Updates and Guidance on SARS-CoV-2 Test Validation

QA Block 1-1
CLARIFIED QUESTION: What types of decisions related to EUAs are being counted in the FDA's daily metrics?
CLARIFIED ANSWER: The FDA's daily metrics for EUAs include original authorizations, supplements and amendments to existing EUAs, pre-EUA feedback, and negative decisions. Updates to existing EUAs can be found via the FDA website.
VERBATIM QUESTION: What types of decisions related to EUAs are being counted in the FDA's daily metrics?
VERBATIM ANSWER: We are currently over the last week averaging about nine decisions. That's N- I-N-E, nine a day. And some of these are of course new original authorizations. They pop up as a new authorization on our FDA Web site. Many of them though are also supplements and amendments to existing EUAs. These don't - these aren't so easily spotted when we make these decisions. But if you go to a given assay and you click on the plus sign for that - on the web site you'll see all of the updates to their authorizations which are the supplements and amendments. Also we consider a decision in our accounting when they issue and close out a pre-EUA feedback. And then of course there are negative decisions and those we don't publicize typically, nor do we publicize, you know, when we close out a pre-EUA submission and give feedback to the developer.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA decision metrics, FDA authorization types, Pre-EUA feedback
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: How can developers identify updates to their existing EUA authorizations on the FDA website?
CLARIFIED ANSWER: Developers can identify updates to their existing EUA authorizations by visiting the assay on the FDA website and clicking the plus sign to view all related updates, including supplements and amendments.
VERBATIM QUESTION: How can developers identify updates to their existing EUA authorizations on the FDA website?
VERBATIM ANSWER: But if you go to a given assay and you click on the plus sign for that - on the web site you'll see all of the updates to their authorizations which are the supplements and amendments.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorizations, FDA website updates
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: Are all decisions made by the FDA about COVID-19 test EUAs publicly disclosed?
CLARIFIED ANSWER: Not all FDA decisions about COVID-19 test EUAs are publicly disclosed, including negative decisions and closed-out pre-EUA feedback.
VERBATIM QUESTION: Are all decisions made by the FDA about COVID-19 test EUAs publicly disclosed?
VERBATIM ANSWER: We are currently over the last week averaging about nine decisions. That's N- I-N-E, nine a day. And some of these are of course new original authorizations. They pop up as a new authorization on our FDA Web site. Many of them though are also supplements and amendments to existing EUAs. These don't - these aren't so easily spotted when we make these decisions. But if you go to a given assay and you click on the plus sign for that - on the web site you'll see all of the updates to their authorizations which are the supplements and amendments. Also we consider a decision in our accounting when they issue and close out a pre-EUA feedback. And then of course there are negative decisions and those we don't publicize typically, nor do we publicize, you know, when we close out a pre-EUA submission and give feedback to the developer. So not all of our decisions are publicly seen easily or at all.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 test EUA decisions, Public disclosure policies, FDA transparency
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: Why are some negative decisions or pre-EUA closeouts not publicized?
CLARIFIED ANSWER: Negative decisions or pre-EUA closeouts are typically not publicized, nor is feedback provided to developers during pre-EUA submissions.
VERBATIM QUESTION: Why are some negative decisions or pre-EUA closeouts not publicized?
VERBATIM ANSWER: And then of course there are negative decisions and those we don't publicize typically, nor do we publicize, you know, when we close out a pre-EUA submission and give feedback to the developer. So not all of our decisions are publicly seen easily or at all.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Negative EUA decisions, Pre-EUA closeouts, FDA decision transparency
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What is the current processing capacity of the FDA in handling new EUA applications compared to the start of the pandemic?
CLARIFIED ANSWER: FDA is now processing around nine decisions per day, compared to one decision per day at the start of the pandemic. This includes new authorizations, amendments, and feedback closures, though not all are publicly visible.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We are currently over the last week averaging about nine decisions. That's N- I-N-E, nine a day. And some of these are of course new original authorizations. They pop up as a new authorization on our FDA Web site. Many of them though are also supplements and amendments to existing EUAs. These don't - these aren't so easily spotted when we make these decisions. But if you go to a given assay and you click on the plus sign for that - on the web site you'll see all of the updates to their authorizations which are the supplements and amendments. Also we consider a decision in our accounting when they issue and close out a pre-EUA feedback. And then of course there are negative decisions and those we don't publicize typically, nor do we publicize, you know, when we close out a pre-EUA submission and give feedback to the developer. So not all of our decisions are publicly seen easily or at all. But we are working harder and faster than ever with more people whereas in the beginning of the pandemic, you know, we were making, you know, when we had an application making maybe one decision today. We're now making nine decisions a day.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA processing capacity, Decision turnaround, COVID-19 diagnostics submissions
REVIEW FLAG: False


#### 2. FDA Guidance on Smartphone Use for Test Interpretation

QA Block 2-1
CLARIFIED QUESTION: What is FDA's current thinking about whether acceptable performance from a clinical study with one representative iPhone model could allow other mobile phone models and operating systems meeting the initial set of critical smartphone specifications to be considered acceptable for use as alternative devices?
CLARIFIED ANSWER: The FDA may require some additional data on other smartphone models even if the clinical study is performed with only one model. A full clinical study may not always be necessary; a comparison study across models might suffice. Further guidance can be obtained through the pre-EUA process to address specific risks.
VERBATIM QUESTION: What is FDA's current thinking about whether acceptable performance from a clinical study with one representative iPhone model could allow other mobile phone models and operating systems meeting the initial set of critical smartphone specifications to be considered acceptable for use as alternative devices?
VERBATIM ANSWER: So for reporting purposes it is not a requirement for an EUA authorization, at least the time of authorization to have a reporting feature. However in what you described we want to make sure on doing the review that the smart phone that you used to capture an analyze the image for determining whether something is positive or negative is accurate and reliable. And so obviously different smart phones are going to have different cameras and different software. So it would be important for us to take a look at what the risks are for using something that's not used in a clinical study. So I can't promise you that we wouldn't ask for some additional data on additional models or manufacturers if you're willing to allow them in your test. However that may not always require necessarily that you do a clinical study but you do some sort of comparison study between the different cell phone models. So that - your question is a great and important one and it's best answered specifically with one of our reviewers through our pre-EUA process. So I wanted to give you at least some flavor of what we've been thinking about and what's important that would help you formulate your questions to our reviewer.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Smartphone specifications for tests, Clinical and comparison studies, FDA's pre-EUA process
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: Does FDA prefer a stepwise approach for manufacturers regarding smartphone models and operating systems?
CLARIFIED ANSWER: The FDA needs to ensure that smartphones used to analyze test results are accurate and reliable. While additional data on other models may be requested, a full clinical study may not always be required; comparison studies might suffice. The process is best clarified through the pre-EUA review.
VERBATIM QUESTION: Does FDA prefer a stepwise approach for manufacturers regarding smartphone models and operating systems?
VERBATIM ANSWER: However in what you described we want to make sure on doing the review that the smart phone that you used to capture an analyze the image for determining whether something is positive or negative is accurate and reliable. And so obviously different smart phones are going to have different cameras and different software. So it would be important for us to take a look at what the risks are for using something that's not used in a clinical study. So I can't promise you that we wouldn't ask for some additional data on additional models or manufacturers if you're willing to allow them in your test. However that may not always require necessarily that you do a clinical study but you do some sort of comparison study between the different cell phone models. So that - your question is a great and important one and it's best answered specifically with one of our reviewers through our pre-EUA process.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone specifications, FDA review process, comparison studies
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: Is this for reporting purposes only or to capture and analyze an image of a device to make a positive or negative call?
CLARIFIED ANSWER: The FDA does not require a reporting feature for EUA authorization, but if a smartphone is used to analyze an image for diagnostic results, its accuracy and reliability must be reviewed. Additional data on other phone models may be requested, but clinical studies may not always be required. The pre-EUA process is recommended for detailed guidance.
VERBATIM QUESTION: Is this for reporting purposes only or to capture and analyze an image of a device to make a positive or negative call?
VERBATIM ANSWER: So for reporting purposes it is not a requirement for an EUA authorization, at least the time of authorization to have a reporting feature. However in what you described we want to make sure on doing the review that the smart phone that you used to capture an analyze the image for determining whether something is positive or negative is accurate and reliable. And so obviously different smart phones are going to have different cameras and different software. So it would be important for us to take a look at what the risks are for using something that's not used in a clinical study. So I can't promise you that we wouldn't ask for some additional data on additional models or manufacturers if you're willing to allow them in your test. However that may not always require necessarily that you do a clinical study but you do some sort of comparison study between the different cell phone models. So that - your question is a great and important one and it's best answered specifically with one of our reviewers through our pre-EUA process. So I wanted to give you at least some flavor of what we've been thinking about and what's important that would help you formulate your questions to our reviewer.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirements, Smartphone diagnostic validation, Pre-EUA review process
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: What are the criteria for determining the accuracy and reliability of a smartphone used to capture and analyze diagnostic test images?
CLARIFIED ANSWER: The FDA ensures that smartphones used to capture and analyze diagnostic test images are accurate and reliable. They assess the risks of using models not clinically studied and may request data on different models, potentially through comparison studies rather than clinical trials.
VERBATIM QUESTION: What are the criteria for determining the accuracy and reliability of a smartphone used to capture and analyze diagnostic test images?
VERBATIM ANSWER: However in what you described we want to make sure on doing the review that the smart phone that you used to capture an analyze the image for determining whether something is positive or negative is accurate and reliable. And so obviously different smart phones are going to have different cameras and different software. So it would be important for us to take a look at what the risks are for using something that's not used in a clinical study. So I can't promise you that we wouldn't ask for some additional data on additional models or manufacturers if you're willing to allow them in your test. However that may not always require necessarily that you do a clinical study but you do some sort of comparison study between the different cell phone models.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Smartphone specification criteria, Diagnostic test imaging, FDA review process
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Can a comparison study between smartphone models be used instead of a full clinical study to validate additional phone models?
CLARIFIED ANSWER: FDA may accept a comparison study between smartphone models instead of a full clinical study to validate additional phone models, but this depends on the risks and specifics of the case. It is advised to consult through the pre-EUA process.
VERBATIM QUESTION: Can a comparison study between smartphone models be used instead of a full clinical study to validate additional phone models?
VERBATIM ANSWER: So for reporting purposes it is not a requirement for an EUA authorization, at least the time of authorization to have a reporting feature. However in what you described we want to make sure on doing the review that the smart phone that you used to capture an analyze the image for determining whether something is positive or negative is accurate and reliable. And so obviously different smart phones are going to have different cameras and different software. So it would be important for us to take a look at what the risks are for using something that's not used in a clinical study. So I can't promise you that we wouldn't ask for some additional data on additional models or manufacturers if you're willing to allow them in your test. However that may not always require necessarily that you do a clinical study but you do some sort of comparison study between the different cell phone models. So that - your question is a great and important one and it's best answered specifically with one of our reviewers through our pre-EUA process. So I wanted to give you at least some flavor of what we've been thinking about and what's important that would help you formulate your questions to our reviewer.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: comparison studies for smartphone validation, EUA process, clinical validation
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: Are there defined risks the FDA evaluates when reviewing smartphones not included in a clinical study for diagnostic tests?
CLARIFIED ANSWER: The FDA evaluates smartphone models for accuracy and reliability, particularly when capturing and analyzing diagnostic images. Different cameras and software may pose risks, and additional data or comparison studies may be required for untested models.
VERBATIM QUESTION: Are there defined risks the FDA evaluates when reviewing smartphones not included in a clinical study for diagnostic tests?
VERBATIM ANSWER: However in what you described we want to make sure on doing the review that the smart phone that you used to capture an analyze the image for determining whether something is positive or negative is accurate and reliable. And so obviously different smart phones are going to have different cameras and different software. So it would be important for us to take a look at what the risks are for using something that's not used in a clinical study. So I can't promise you that we wouldn't ask for some additional data on additional models or manufacturers if you're willing to allow them in your test. However that may not always require necessarily that you do a clinical study but you do some sort of comparison study between the different cell phone models.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone evaluations, clinical study alternatives, diagnostic test risks
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: What type of data might the FDA request to support the inclusion of additional smartphone models or manufacturers for a diagnostic test?
CLARIFIED ANSWER: The FDA may request additional data to ensure accuracy and reliability of other smartphone models or manufacturers for capturing and analyzing diagnostic images. This might include a comparison study rather than a full clinical study.
VERBATIM QUESTION: What type of data might the FDA request to support the inclusion of additional smartphone models or manufacturers for a diagnostic test?
VERBATIM ANSWER: However in what you described we want to make sure on doing the review that the smart phone that you used to capture an analyze the image for determining whether something is positive or negative is accurate and reliable. And so obviously different smart phones are going to have different cameras and different software. So it would be important for us to take a look at what the risks are for using something that's not used in a clinical study. So I can't promise you that we wouldn't ask for some additional data on additional models or manufacturers if you're willing to allow them in your test. However that may not always require necessarily that you do a clinical study but you do some sort of comparison study between the different cell phone models.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone compatibility, diagnostic test validation, FDA data requirements
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: Does the inclusion of a reporting feature in a mobile diagnostic app impact the EUA authorization process?
CLARIFIED ANSWER: The inclusion of a reporting feature is not a requirement for EUA authorization. However, for a mobile diagnostic app that captures and analyzes images, the FDA reviews the accuracy and reliability of smartphones used. Different phone models and software may require additional data or studies, which can sometimes be comparison studies rather than clinical.
VERBATIM QUESTION: Does the inclusion of a reporting feature in a mobile diagnostic app impact the EUA authorization process?
VERBATIM ANSWER: So for reporting purposes it is not a requirement for an EUA authorization, at least the time of authorization to have a reporting feature. However in what you described we want to make sure on doing the review that the smart phone that you used to capture an analyze the image for determining whether something is positive or negative is accurate and reliable. And so obviously different smart phones are going to have different cameras and different software. So it would be important for us to take a look at what the risks are for using something that's not used in a clinical study. So I can't promise you that we wouldn't ask for some additional data on additional models or manufacturers if you're willing to allow them in your test. However that may not always require necessarily that you do a clinical study but you do some sort of comparison study between the different cell phone models.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirements, Mobile app features, Data requirements
REVIEW FLAG: False


#### 3. PCR vs Antigen Testing: Accuracy, Applications, and FDA Perspective

QA Block 3-1
CLARIFIED QUESTION: What is the FDA's current thinking on PCR versus antigen tests and when they could be optimally used?
CLARIFIED ANSWER: The FDA supports both molecular and antigen tests, considering their strengths and weaknesses. Molecular tests are generally more sensitive and can detect infections even after the infectious period is over, whereas antigen tests are less sensitive but better at identifying contagious individuals. Molecular tests are better suited for high-complexity labs, while antigen tests are more scalable and easier to use in point-of-care and home settings.
VERBATIM QUESTION: What is the FDA's current thinking on PCR versus antigen tests and when they could be optimally used?
VERBATIM ANSWER: Regarding molecular versus antigen, obviously we support both. From the FDA perspective our job is to take a look at the different technologies that can be brought to bear to help this pandemic and make sure that they are accurate and safe to use and that's our main consideration. We're very supportive of all types of testing whether it's molecular, molecular point-of-care, molecular center lab, central lab or antigen point-of-care, antigen home, molecular home, molecular OTC, antigen OTC. So we see that they're all able to assist in this pandemic. We know that in general molecular assays are more sensitive than antigen assays and there are some - therefore some trade-offs both ways. I mean some people have said molecular assays are too sensitive, you know. And I think, you know, if you're looking at asymptomatic people and you don't know when they got infected a molecular test might identify somebody, you know, a week or two or more after they became infected and maybe they're not as infectious or are not infectious any longer versus antigen tests which are usually require more intact virus and aren't as sensitive. Probably, you know, the good ones are, and the ones I think that we've authorized are good ones, are probably better able to tell, you know, who are the patients that are positive and truly positive. You know, those are probably patients that you want to make sure that you take appropriate measures to make sure that they don't transmit that to somebody else. So the other thing is, you know, for central lab testing especially very high throughput, you know, unless you have an instrument that - and we have authorized one central lab antigen test, you know, and that's fairly high- volume but it's a lot easier to make the molecular test and do it in large volumes in a central lab. But obviously a central lab is the high complexity lab environment and, you know, a point of care clinic, you know, would, you know, not be able to do a high complexity lab test but they can do waived or a deemed waived test. And so and also at home it would be similar sort of easy to use. And it's a lot easier to make an antigen test point of care and a minimal to home than a molecular for obvious reasons.
SPEAKER QUESTION: Greg Slovatkin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: PCR vs. antigen tests, optimal test usage, sensitivity differences
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: Why is FDA still issuing EUAs that require a prescription for a test when there is a desperate need for mass testing?
CLARIFIED ANSWER: FDA issues EUAs requiring prescriptions to mitigate risks and ensure accurate testing by involving clinicians. They have authorized over-the-counter tests for developers who complete additional validation.
VERBATIM QUESTION: Why is FDA still issuing EUAs that require a prescription for a test when there is a desperate need for mass testing?
VERBATIM ANSWER: So Rx let's start with that is a mitigation on risk. So if patients, you know, don't have a clinician involved with interpreting the test then we look at other mitigations to ensure accurate testing and that the reading of the test and the interpretation of the test is also good in the hands of the consumer. So we are in - or we've authorized OTC tests that are without prescription. And so we are clearly very open to it. But we do ask for additional validation work for that. And, you know, as long as developers are willing to do those extra steps we're willing to give an over-the-counter claim to that assay.
SPEAKER QUESTION: Greg Slovatkin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirements, Prescription testing, Over-the-counter testing
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Does the FDA still maintain that there is a higher chance of false negatives for antigen tests compared to molecular tests?
CLARIFIED ANSWER: The FDA confirms that antigen tests are more likely to produce false negatives, especially in symptomatic individuals within the first 5-7 days of symptoms, compared to a good central molecular test. This is why antigen test labeling states negatives as presumed negative.
VERBATIM QUESTION: Does the FDA still maintain that there is a higher chance of false negatives for antigen tests compared to molecular tests?
VERBATIM ANSWER: Oh very clearly antigen tests are more likely to have false negatives especially in important false negatives, especially in the first, you know, zero - day zero to day five or day zero to day seven. Performance is clearly lower in that period of time for symptomatic people than a real good central molecular test. So you're going to have negative results with an antigen test that will be on somebody who's symptomatic and has SARS. And you'd have to do a lot of hand waving to convince me that somebody in the first few days is symptomatic infection can't be infectious. And they're going to be falsely negative as sometimes in an antigen test, less likely to be false-negative with a good central molecular test. So it's why our labeling for antigen tests all say the negatives are presumed negative rather than negative.
SPEAKER QUESTION: Greg Slovatkin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: False negatives in COVID-19 tests, Antigen vs Molecular tests
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What additional validation work is required to obtain over-the-counter (OTC) authorization for a test?
CLARIFIED ANSWER: FDA requires additional validation work to ensure that OTC tests are accurate and can be interpreted correctly by consumers without clinician involvement. Developers who complete these steps can obtain OTC authorization.
VERBATIM QUESTION: What additional validation work is required to obtain over-the-counter (OTC) authorization for a test?
VERBATIM ANSWER: So Rx let's start with that is a mitigation on risk. So if patients, you know, don't have a clinician involved with interpreting the test then we look at other mitigations to ensure accurate testing and that the reading of the test and the interpretation of the test is also good in the hands of the consumer. So we are in - or we've authorized OTC tests that are without prescription. And so we are clearly very open to it. But we do ask for additional validation work for that. And, you know, as long as developers are willing to do those extra steps we're willing to give an over-the-counter claim to that assay.
SPEAKER QUESTION: Greg Slovatkin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC test authorization, Validation requirements
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: Are there specific strengths and weaknesses of central lab antigen testing versus central lab molecular testing that developers should consider?
CLARIFIED ANSWER: FDA states that molecular assays are generally more sensitive than antigen assays, making molecular tests useful for identifying infections even late or in asymptomatic individuals, whereas antigen tests may better identify infectious individuals. Central lab molecular tests are easier for high-volume processing than antigen tests.
VERBATIM QUESTION: Are there specific strengths and weaknesses of central lab antigen testing versus central lab molecular testing that developers should consider?
VERBATIM ANSWER: We know that in general molecular assays are more sensitive than antigen assays and there are some - therefore some trade-offs both ways. I mean some people have said molecular assays are too sensitive, you know. And I think, you know, if you're looking at asymptomatic people and you don't know when they got infected a molecular test might identify somebody, you know, a week or two or more after they became infected and maybe they're not as infectious or are not infectious any longer versus antigen tests which are usually require more intact virus and aren't as sensitive. Probably, you know, the good ones are, and the ones I think that we've authorized are good ones, are probably better able to tell, you know, who are the patients that are positive and truly positive. You know, those are probably patients that you want to make sure that you take appropriate measures to make sure that they don't transmit that to somebody else. So the other thing is, you know, for central lab testing especially very high throughput, you know, unless you have an instrument that - and we have authorized one central lab antigen test, you know, and that's fairly high- volume but it's a lot easier to make the molecular test and do it in large volumes in a central lab.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: central lab antigen vs. molecular testing, test sensitivity, use cases for specific tests
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: How does the FDA view the trade-offs between the sensitivity of molecular tests and the situational usefulness of antigen tests?
CLARIFIED ANSWER: The FDA supports both molecular and antigen tests, recognizing their different sensitivities and situational uses. Molecular tests are generally more sensitive, detecting infections even when individuals may no longer be infectious, while antigen tests are better at identifying actively infectious individuals. The FDA assesses each test to ensure accuracy and safety.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Regarding molecular versus antigen, obviously we support both. From the FDA perspective our job is to take a look at the different technologies that can be brought to bear to help this pandemic and make sure that they are accurate and safe to use and that's our main consideration. We're very supportive of all types of testing whether it's molecular, molecular point-of-care, molecular center lab, central lab or antigen point-of-care, antigen home, molecular home, molecular OTC, antigen OTC. So we see that they're all able to assist in this pandemic. We know that in general molecular assays are more sensitive than antigen assays and there are some - therefore some trade-offs both ways. I mean some people have said molecular assays are too sensitive, you know. And I think, you know, if you're looking at asymptomatic people and you don't know when they got infected a molecular test might identify somebody, you know, a week or two or more after they became infected and maybe they're not as infectious or are not infectious any longer versus antigen tests which are usually require more intact virus and aren't as sensitive. Probably, you know, the good ones are, and the ones I think that we've authorized are good ones, are probably better able to tell, you know, who are the patients that are positive and truly positive. You know, those are probably patients that you want to make sure that you take appropriate measures to make sure that they don't transmit that to somebody else.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sensitivity of molecular tests, antigen vs molecular test uses, FDA test assessment
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: Does the FDA provide specific labeling requirements for antigen test results, such as presumed negative warnings?
CLARIFIED ANSWER: The FDA requires antigen test labeling to state that negative results are presumed negative due to a higher chance of false negatives, particularly in the early days of symptomatic infection.
VERBATIM QUESTION: Does the FDA provide specific labeling requirements for antigen test results, such as presumed negative warnings?
VERBATIM ANSWER: Oh very clearly antigen tests are more likely to have false negatives especially in important false negatives, especially in the first, you know, zero - day zero to day five or day zero to day seven. Performance is clearly lower in that period of time for symptomatic people than a real good central molecular test. So you're going to have negative results with an antigen test that will be on somebody who's symptomatic and has SARS. And you'd have to do a lot of hand waving to convince me that somebody in the first few days is symptomatic infection can't be infectious. And they're going to be falsely negative as sometimes in an antigen test, less likely to be false-negative with a good central molecular test. So it's why our labeling for antigen tests all say the negatives are presumed negative rather than negative.
SPEAKER QUESTION: Greg Slovatkin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test labeling, False negative results, FDA regulations
REVIEW FLAG: False

QA Block 3-8
CLARIFIED QUESTION: Are there technological challenges unique to creating point-of-care or home-use molecular tests compared to antigen tests?
CLARIFIED ANSWER: Antigen tests are easier to create for point-of-care or home use compared to molecular tests. Additionally, when manufactured reliably, they can achieve extremely high production volumes, unlike molecular tests.
VERBATIM QUESTION: Are there technological challenges unique to creating point-of-care or home-use molecular tests compared to antigen tests?
VERBATIM ANSWER: And it's a lot easier to make an antigen test point of care and a minimal to home than a molecular for obvious reasons. The other thing an advantage that antigen test can have is when they're good and they can be manufactured reliably which is a hard thing to do, they can be made in the millions of tests per month or more. I mean you've seen the press reports from some of the manufacturers upwards of 50 million and maybe going up to 100 million tests from a single manufacturer, single antigen test per month.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care/home-use test production, Comparison: antigen vs molecular tests
REVIEW FLAG: False

QA Block 3-9
CLARIFIED QUESTION: What considerations determine whether a test is waived or deemed waived for point-of-care use?
CLARIFIED ANSWER: Tests deemed waived for point-of-care use must be easy to use, as high-complexity lab tests cannot be conducted in such settings.
VERBATIM QUESTION: What considerations determine whether a test is waived or deemed waived for point-of-care use?
VERBATIM ANSWER: Obviously a central lab is the high complexity lab environment and, you know, a point of care clinic, you know, would, you know, not be able to do a high complexity lab test but they can do waived or a deemed waived test. And so and also at home it would be similar sort of easy to use.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test waiver considerations, Point-of-care diagnostics
REVIEW FLAG: False

QA Block 3-10
CLARIFIED QUESTION: Is the FDA monitoring production scalability when authorizing antigen tests, and if so, how does it evaluate this capability?
CLARIFIED ANSWER: The FDA recognizes that manufacturing reliable antigen tests is challenging but sees their potential for large-scale production, possibly up to 100 million per month from some manufacturers, far surpassing molecular test production.
VERBATIM QUESTION: Is the FDA monitoring production scalability when authorizing antigen tests, and if so, how does it evaluate this capability?
VERBATIM ANSWER: The other thing an advantage that antigen test can have is when they're good and they can be manufactured reliably which is a hard thing to do, they can be made in the millions of tests per month or more. I mean you've seen the press reports from some of the manufacturers upwards of 50 million and maybe going up to 100 million tests from a single manufacturer, single antigen test per month. And those are volumes that, you know, are potentially order - in order or orders of magnitude greater than what the molecular manufactures and obviously individual labs, you know, central labs can test for.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test production, Scalability evaluation
REVIEW FLAG: False


#### 4. Smartphone Updates and Test Validation for At-Home Diagnostics

QA Block 4-1
CLARIFIED QUESTION: What are the agency's expectations around system validation or updating after major updates to a smartphone operating system?
CLARIFIED ANSWER: The FDA expects test developers to monitor for smartphone OS updates and maintain relationships with manufacturers to prepare for changes. If test performance is affected, the FDA should be notified immediately. Developers should also discuss plans for managing OS updates during their EUA submission to possibly enable built-in change control for updates.
VERBATIM QUESTION: What are the agency's expectations around system validation or updating after major updates to a smartphone operating system?
VERBATIM ANSWER: I think it's just, you know, a wise thing to do for a test developer to monitor that. I mean ideally a test developer would have relationships with the manufacturers of phones or sellers of phones that they're using so that they can know ahead of time when an update might be coming. You know, but if suddenly an update is made and it changes the performance of your test the FDA is going to want to know that right away. And if you're giving now inaccurate results out, you know, then that's - that would be a public health of public health importance. And also would note that, you know, one thing that we recommend is that you discuss this topic specifically with your review team when you have your EUA request in because we would be interested in seeing your plans for addressing periodic operating system updates since obviously everyone knows that that happens. And depending on how robust your procedures are for handling those we may be able to build in some change control into an EUA.
SPEAKER QUESTION: Marianne Fikner
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone OS updates, test validation, emergency use authorization (EUA)
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: What steps should a test developer take to monitor smartphone operating system updates?
CLARIFIED ANSWER: Developers should monitor updates, build relationships with phone manufacturers to anticipate changes, and report any updates that affect test performance. Discussing update plans with FDA review teams during EUA submissions is also advised.
VERBATIM QUESTION: What steps should a test developer take to monitor smartphone operating system updates?
VERBATIM ANSWER: I think it's just, you know, a wise thing to do for a test developer to monitor that. I mean ideally a test developer would have relationships with the manufacturers of phones or sellers of phones that they're using so that they can know ahead of time when an update might be coming. You know, but if suddenly an update is made and it changes the performance of your test the FDA is going to want to know that right away. And if you're giving now inaccurate results out, you know, then that's - that would be a public health of public health importance. And also would note that, you know, one thing that we recommend is that you discuss this topic specifically with your review team when you have your EUA request in because we would be interested in seeing your plans for addressing periodic operating system updates since obviously everyone knows that that happens. And depending on how robust your procedures are for handling those we may be able to build in some change control into an EUA.
SPEAKER QUESTION: Marianne Fikner
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Smartphone OS updates, System validation, EUA procedures
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Does the FDA expect test developers to establish relationships with smartphone manufacturers to anticipate system updates?
CLARIFIED ANSWER: The FDA encourages test developers to establish relationships with smartphone manufacturers to anticipate updates, monitor performance changes, and promptly address public health concerns related to test inaccuracy.
VERBATIM QUESTION: Does the FDA expect test developers to establish relationships with smartphone manufacturers to anticipate system updates?
VERBATIM ANSWER: I think it's just, you know, a wise thing to do for a test developer to monitor that. I mean ideally a test developer would have relationships with the manufacturers of phones or sellers of phones that they're using so that they can know ahead of time when an update might be coming. You know, but if suddenly an update is made and it changes the performance of your test the FDA is going to want to know that right away. And if you're giving now inaccurate results out, you know, then that's - that would be a public health of public health importance.
SPEAKER QUESTION: Marianne Fikner
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone app system updates, test developer partnerships, FDA public health expectations
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: What should a test developer do if an operating system update negatively impacts test performance?
CLARIFIED ANSWER: Test developers should monitor for operating system updates and establish communication with phone manufacturers to anticipate changes. If performance is negatively impacted, they must notify FDA immediately, especially if inaccurate results are being delivered.
VERBATIM QUESTION: What should a test developer do if an operating system update negatively impacts test performance?
VERBATIM ANSWER: I think it's just, you know, a wise thing to do for a test developer to monitor that. I mean ideally a test developer would have relationships with the manufacturers of phones or sellers of phones that they're using so that they can know ahead of time when an update might be coming. You know, but if suddenly an update is made and it changes the performance of your test the FDA is going to want to know that right away. And if you're giving now inaccurate results out, you know, then that's - that would be a public health of public health importance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OS updates impacting test performance, FDA reporting requirements
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: How can developers incorporate plans for handling operating system updates into their EUA submissions?
CLARIFIED ANSWER: FDA recommends discussing plans for addressing periodic operating system updates with the review team during the EUA submission process. Robust procedures may allow inclusion of change control mechanisms in the EUA.
VERBATIM QUESTION: How can developers incorporate plans for handling operating system updates into their EUA submissions?
VERBATIM ANSWER: And also would note that, you know, one thing that we recommend is that you discuss this topic specifically with your review team when you have your EUA request in because we would be interested in seeing your plans for addressing periodic operating system updates since obviously everyone knows that that happens. And depending on how robust your procedures are for handling those we may be able to build in some change control into an EUA.
SPEAKER QUESTION: Marianne Fikner
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submissions, Operating system updates, Change control
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What is the FDA's guidance on building change control procedures into EUA applications for addressing periodic operating system updates?
CLARIFIED ANSWER: The FDA recommends discussing plans for addressing operating system updates with the review team when submitting an EUA; robust procedures may allow for incorporating change control mechanisms into the EUA.
VERBATIM QUESTION: What is the FDA's guidance on building change control procedures into EUA applications for addressing periodic operating system updates?
VERBATIM ANSWER: One thing that we recommend is that you discuss this topic specifically with your review team when you have your EUA request in because we would be interested in seeing your plans for addressing periodic operating system updates since obviously everyone knows that that happens. And depending on how robust your procedures are for handling those we may be able to build in some change control into an EUA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: change control, operating system updates, EUA applications
REVIEW FLAG: False


#### 5. Validation Requirements for SARS-CoV-2 Sample Pooling Claims

QA Block 5-1
CLARIFIED QUESTION: If a test developer wishes to seek a sample pooling claim for the SARS-CoV-2 target in a molecular multi-analyte test, would it be necessary to validate and obtain a pooling claim for the non-COVID influenza or respiratory targets?
CLARIFIED ANSWER: If the non-COVID results are masked in a molecular multi-analyte test, validation for non-COVID targets is not necessary.
VERBATIM QUESTION: If a test developer wishes to seek a sample pooling claim for the SARS-CoV-2 target in a molecular multi-analyte test, would it be necessary to validate and obtain a pooling claim for the non-COVID influenza or respiratory targets?
VERBATIM ANSWER: And if they would mask the other results then you wouldn't need to validate, you know, for the other analytes if you mask them.
SPEAKER QUESTION: Mark Delvecchio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample pooling, validation requirements, molecular multi-analyte tests
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Is there a mechanism to obtain a pooling claim just for the COVID target in a molecular multi-analyte test, such as a labeling restriction or masking other results?
CLARIFIED ANSWER: A mechanism exists to obtain a pooling claim just for the COVID target by masking other results, removing the need to validate for the other analytes.
VERBATIM QUESTION: Is there a mechanism to obtain a pooling claim just for the COVID target in a molecular multi-analyte test, such as a labeling restriction or masking other results?
VERBATIM ANSWER: And if they would mask the other results then you wouldn't need to validate, you know, for the other analytes if you mask them.
SPEAKER QUESTION: Mark Delvecchio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pooling claim for COVID testing, molecular multi-analyte tests, validation for non-COVID targets
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What are the FDA's recommendations or mitigation strategies for pooling validation when focusing only on SARS-CoV-2 in a molecular multi-analyte test?
CLARIFIED ANSWER: The FDA suggests masking non-SARS results in molecular multi-analyte tests to focus on SARS-CoV-2 pooling validation only, avoiding the need to validate non-COVID analytes.
VERBATIM QUESTION: What are the FDA's recommendations or mitigation strategies for pooling validation when focusing only on SARS-CoV-2 in a molecular multi-analyte test?
VERBATIM ANSWER: Yes well that would be an effective mitigation is that if someone wants to pool they're probably pooling mostly for SARS, not for the other diseases right? And if they would mask the other results then you wouldn't need to validate, you know, for the other analytes if you mask them.
SPEAKER QUESTION: Mark Delvecchio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pooling validation, SARS-CoV-2, molecular multi-analyte test
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: If masking the non-COVID analytes in a molecular multi-analyte test is used as a mitigation strategy, would further validation for those analytes still be necessary?
CLARIFIED ANSWER: If non-COVID analytes are masked in a molecular multi-analyte test, additional validation for those analytes is not required.
VERBATIM QUESTION: If masking the non-COVID analytes in a molecular multi-analyte test is used as a mitigation strategy, would further validation for those analytes still be necessary?
VERBATIM ANSWER: And if they would mask the other results then you wouldn't need to validate, you know, for the other analytes if you mask them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validation requirements, molecular multi-analyte tests, masking strategy
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: Is it possible to pool only for SARS-CoV-2 testing in a multi-analyte test while excluding other targets?
CLARIFIED ANSWER: It is possible to pool solely for SARS-CoV-2 testing in a multi-analyte test by masking other results, avoiding the need for additional validation for non-COVID targets.
VERBATIM QUESTION: Is it possible to pool only for SARS-CoV-2 testing in a multi-analyte test while excluding other targets?
VERBATIM ANSWER: And if they would mask the other results then you wouldn't need to validate, you know, for the other analytes if you mask them.
SPEAKER QUESTION: Mark Delvecchio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pooling for SARS-CoV-2, multi-analyte tests, masking non-COVID results
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: Are there conditions or requirements for masking non-COVID results in a molecular multi-analyte test to focus on pooled SARS-CoV-2 testing?
CLARIFIED ANSWER: If non-COVID results are masked in a molecular multi-analyte test, validation for the other analytes is not needed.
VERBATIM QUESTION: Are there conditions or requirements for masking non-COVID results in a molecular multi-analyte test to focus on pooled SARS-CoV-2 testing?
VERBATIM ANSWER: And if they would mask the other results then you wouldn't need to validate, you know, for the other analytes if you mask them.
SPEAKER QUESTION: Mark Delvecchio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: masking non-COVID results, multi-analyte tests, validation requirements
REVIEW FLAG: False


#### 6. Antigen Test Validation for Nasal or Nasopharyngeal Swabs

QA Block 6-1
CLARIFIED QUESTION: Is it true for antigen tests that if a test is validated for NP swabs, it can also be used for anterior nasal swabs without additional validation?
CLARIFIED ANSWER: For antigen tests, additional validation with patient data is needed for anterior nasal swabs due to sensitivity differences between nasopharyngeal and anterior samples. FDA encourages validation for more user-friendly swab types like anterior nares or mid-turbinate swabs.
VERBATIM QUESTION: Is it true for antigen tests that if a test is validated for NP swabs, it can also be used for anterior nasal swabs without additional validation?
VERBATIM ANSWER: Yes to talk specifically about the antigen test yes we would ask to see patient data for anterior nasal swab. And the antigen tests are less sensitive. They're more sensitive to differences in viral loads that might happen between the nasopharynx and the anterior. So and it's important to understand that performance difference. Now we're not requiring for an antigen test that they do a nasopharyngeal swab. A matter of fact I encourage most to try to validate and get their recommended sensitivity with anterior nares or, you know, worst-case mid- turbinate swabs because those are much better tolerated. They can be if you validate it for self-collection they can be self-collected. They are then amenable if you have a good antigen test and it's easy to use for home use either prescription or over-the-counter. So, you know, whereas, you know, a consumer cannot perform nasopharyngeal swab on them selves, at least not safely.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validation of antigen tests, swab type requirements, sensitivity differences
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: Are there specific reasons or advantages for validating antigen tests with anterior nasal swabs or mid-turbinate swabs?
CLARIFIED ANSWER: The FDA advises validating antigen tests specifically with anterior nasal or mid-turbinate swabs because antigen tests are more sensitive to viral load differences across collection sites. These swabs are better tolerated, can allow for self-collection, and enable home use options, unlike nasopharyngeal swabs which are not safe for self-administration.
VERBATIM QUESTION: Are there specific reasons or advantages for validating antigen tests with anterior nasal swabs or mid-turbinate swabs?
VERBATIM ANSWER: Yes to talk specifically about the antigen test yes we would ask to see patient data for anterior nasal swab. And the antigen tests are less sensitive. They're more sensitive to differences in viral loads that might happen between the nasopharynx and the anterior. So and it's important to understand that performance difference. Now we're not requiring for an antigen test that they do a nasopharyngeal swab. A matter of fact I encourage most to try to validate and get their recommended sensitivity with anterior nares or, you know, worst-case mid- turbinate swabs because those are much better tolerated. They can be if you validate it for self-collection they can be self-collected. They are then amenable if you have a good antigen test and it's easy to use for home use either prescription or over-the-counter. So, you know, whereas, you know, a consumer cannot perform nasopharyngeal swab on them selves, at least not safely.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of antigen tests, Anterior nasal and mid-turbinate swabs, Advantages of self-collection
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Can antigen tests validated with anterior nasal swabs be used for self-collection or home use?
CLARIFIED ANSWER: FDA suggests that antigen tests validated with anterior nasal swabs can be used for self-collection and are suitable for home use if they are sensitive and easy to use.
VERBATIM QUESTION: Can antigen tests validated with anterior nasal swabs be used for self-collection or home use?
VERBATIM ANSWER: Yes to talk specifically about the antigen test yes we would ask to see patient data for anterior nasal swab. And the antigen tests are less sensitive. They're more sensitive to differences in viral loads that might happen between the nasopharynx and the anterior. So and it's important to understand that performance difference. Now we're not requiring for an antigen test that they do a nasopharyngeal swab. A matter of fact I encourage most to try to validate and get their recommended sensitivity with anterior nares or, you know, worst-case mid- turbinate swabs because those are much better tolerated. They can be if you validate it for self-collection they can be self-collected. They are then amenable if you have a good antigen test and it's easy to use for home use either prescription or over-the-counter. So, you know, whereas, you know, a consumer cannot perform nasopharyngeal swab on them selves, at least not safely.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test validation, self-collection, home use
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: Is it necessary to demonstrate performance differences between nasopharyngeal and anterior nasal swabs for antigen tests?
CLARIFIED ANSWER: Yes, for antigen tests, FDA requires manufacturers to provide patient data for anterior nasal swabs. Performance differences between nasopharyngeal and anterior nasal swabs should be understood, and validating with anterior nasal swabs is encouraged as they are less invasive and can be self-collected.
VERBATIM QUESTION: Is it necessary to demonstrate performance differences between nasopharyngeal and anterior nasal swabs for antigen tests?
VERBATIM ANSWER: Yes to talk specifically about the antigen test yes we would ask to see patient data for anterior nasal swab. And the antigen tests are less sensitive. They're more sensitive to differences in viral loads that might happen between the nasopharynx and the anterior. So and it's important to understand that performance difference. Now we're not requiring for an antigen test that they do a nasopharyngeal swab. A matter of fact I encourage most to try to validate and get their recommended sensitivity with anterior nares or, you know, worst-case mid- turbinate swabs because those are much better tolerated. They can be if you validate it for self-collection they can be self-collected. They are then amenable if you have a good antigen test and it's easy to use for home use either prescription or over-the-counter. So, you know, whereas, you know, a consumer cannot perform nasopharyngeal swab on them selves, at least not safely.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test performance, nasopharyngeal vs nasal swabs, validation requirements
REVIEW FLAG: False

QA Block 6-8
CLARIFIED QUESTION: How does the FDA recommend validating COVID-19 antigen tests for home use or over-the-counter use?
CLARIFIED ANSWER: The FDA recommends validating antigen tests for sensitivity using anterior nares or mid-turbinate swabs, as these are better tolerated, suitable for self-collection, and appropriate for home-use scenarios, either prescription-based or over-the-counter.
VERBATIM QUESTION: How does the FDA recommend validating COVID-19 antigen tests for home use or over-the-counter use?
VERBATIM ANSWER: And the antigen tests are less sensitive. They're more sensitive to differences in viral loads that might happen between the nasopharynx and the anterior. So and it's important to understand that performance difference. Now we're not requiring for an antigen test that they do a nasopharyngeal swab. A matter of fact I encourage most to try to validate and get their recommended sensitivity with anterior nares or, you know, worst-case mid- turbinate swabs because those are much better tolerated. They can be if you validate it for self-collection they can be self-collected. They are then amenable if you have a good antigen test and it's easy to use for home use either prescription or over-the-counter.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of antigen tests, Home use diagnostics, Over-the-counter use
REVIEW FLAG: False


#### 7. Guidance for COVID Breath Test Development and Sensitivity Requirements

QA Block 7-1
CLARIFIED QUESTION: Do you have any updates or current thoughts on the PPA or sensitivity requirements for a breath test for screening COVID?
CLARIFIED ANSWER: FDA's current thinking is that the benefit-risk balance of breath tests favors use in asymptomatic populations, requiring high sensitivity. Novel technology like this might need more positive cases for approval compared to antigen or molecular tests. Cross-reactivity testing would involve symptomatic individuals undergoing SARS and respiratory panel testing. Additional details can be provided via email.
VERBATIM QUESTION: Do you have any updates or current thoughts on the PPA or sensitivity requirements for a breath test for screening COVID?
VERBATIM ANSWER: Yes we do. I can give you some of our current thinking and philosophy as it comes to breath test. This is all still being developed so I wouldn't - but I think our team can provide you with even more specifics if you sent an email to the templates email mailbox. But I want to point you in sort of the flavor of where we're going here so you understand and can ask good questions hopefully. One is when you think about the benefit risk of a breath test and in aiding in this pandemic, you know, if somebody is symptomatic versus somebody who is asymptomatic, the benefit risk favors testing the asymptomatic populations with a novel device such as this, especially if it has a high sensitivity in the asymptomatic population. You know, if someone's symptomatic and it's a totally novel device when they're, you know, when they're, you know, when the concern about finding positive people is more moving into the asymptomatic population now as we try to control the spread of disease. If someone's symptomatic they should be isolating, you know, and masking and all those things and get tests but if the tests don't make sense then. So the benefit risk really favors using the breath test in the asymptomatic population. We would want to see that, you know, it has a relatively high sensitivity in asymptomatic population. And since this is a novel technology and we don't have the same sort of experience, you know, even with other respiratory viruses like we do with molecular and antigen we will probably want to see more positives in the asymptomatic population than we would ask for an antigen or a molecular test for authorization of asymptomatic screening because we want to make sure it's not going to be, you know, orders of magnitude more. It's just going to be a little bit more but we think still reasonable. And the other thing is with a breath test it's really hard to do cross-reactivity testing. Now first of all the actual analyte isn't the virus or other viruses. It's, you know, volatiles. And so how do you get at cross reactivity? And really the only way we could think of that's very doable and will allow developers like yourself to move forward is to test symptomatic people with a SARS test and also a respiratory panel test. Both should be authorized. There are some respiratory panels that have - and they've been authorized that have SARS on it so it would be one test. But you test, you know, a sufficient number of symptomatic people, somewhere around maybe 5% or 10%, maybe 10% of them are going to have SARS today of the symptomatic population. The rest of them are going to have some other respiratory disease, mostly viral, you know, rhino non-novel corona, et cetera, RSV, some flu, et cetera. So you should without having to test that many patients you should be able to see, you know, and a good panel that would detect most of the non-SARS viruses that are infecting patients these days and causing symptoms, you wouldn't take that many patients who are symptomatic with this kind of comparison study to show if a breath test is specific for SARS or not. So that's our current thinking. If you send us an email at our templates email address for an update on our current recommendations and thinking for breath tests, we can provide you with some more information than we have in the past okay?
SPEAKER QUESTION: Anna Gozrelli
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Breath test sensitivity requirements, Asymptomatic COVID screening, Cross-reactivity testing for diagnostic devices
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: What population is most appropriate to target for a breath test, symptomatic or asymptomatic?
CLARIFIED ANSWER: The FDA recommends targeting asymptomatic populations for breath tests, as the benefit-risk assessment supports this approach, especially if the tests have high sensitivity for asymptomatic individuals.
VERBATIM QUESTION: What population is most appropriate to target for a breath test, symptomatic or asymptomatic?
VERBATIM ANSWER: One is when you think about the benefit risk of a breath test and in aiding in this pandemic, you know, if somebody is symptomatic versus somebody who is asymptomatic, the benefit risk favors testing the asymptomatic populations with a novel device such as this, especially if it has a high sensitivity in the asymptomatic population. You know, if someone's symptomatic and it's a totally novel device when they're, you know, when they're, you know, when the concern about finding positive people is more moving into the asymptomatic population now as we try to control the spread of disease. If someone's symptomatic they should be isolating, you know, and masking and all those things and get tests but if the tests don't make sense then. So the benefit risk really favors using the breath test in the asymptomatic population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: breath test targeting, asymptomatic testing, FDA recommendations
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: What level of sensitivity is considered relatively high for asymptomatic populations in novel breath tests?
CLARIFIED ANSWER: The FDA considers relatively high sensitivity for asymptomatic populations in novel breath tests to involve identifying more positive cases than antigen or molecular tests require for authorization, while remaining within a reasonable range.
VERBATIM QUESTION: What level of sensitivity is considered relatively high for asymptomatic populations in novel breath tests?
VERBATIM ANSWER: We would want to see that, you know, it has a relatively high sensitivity in asymptomatic population. And since this is a novel technology and we don't have the same sort of experience, you know, even with other respiratory viruses like we do with molecular and antigen we will probably want to see more positives in the asymptomatic population than we would ask for an antigen or a molecular test for authorization of asymptomatic screening because we want to make sure it's not going to be, you know, orders of magnitude more. It's just going to be a little bit more but we think still reasonable.
SPEAKER QUESTION: Anna Gozrelli
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sensitivity for asymptomatic breath tests, Authorization criteria, Novel COVID-19 diagnostics
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: Why does the FDA require more positive cases for breath tests compared to antigen or molecular tests for asymptomatic screening?
CLARIFIED ANSWER: The FDA requires more positive cases for breath tests in asymptomatic screening compared to molecular or antigen tests due to the novelty of the technology and limited prior experience in respiratory virus testing.
VERBATIM QUESTION: Why does the FDA require more positive cases for breath tests compared to antigen or molecular tests for asymptomatic screening?
VERBATIM ANSWER: And since this is a novel technology and we don't have the same sort of experience, you know, even with other respiratory viruses like we do with molecular and antigen we will probably want to see more positives in the asymptomatic population than we would ask for an antigen or a molecular test for authorization of asymptomatic screening because we want to make sure it's not going to be, you know, orders of magnitude more. It's just going to be a little bit more but we think still reasonable.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: breath test validation, asymptomatic screening, FDA requirements
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: How can developers demonstrate cross-reactivity testing for breath tests, given the analyte is not a virus?
CLARIFIED ANSWER: To demonstrate cross-reactivity testing for breath tests, FDA suggests testing symptomatic individuals using both an authorized SARS test and a respiratory panel test that includes a variety of respiratory viruses. Testing a sufficient number of symptomatic patients should allow assessment of test specificity without requiring excessive trials.
VERBATIM QUESTION: How can developers demonstrate cross-reactivity testing for breath tests, given the analyte is not a virus?
VERBATIM ANSWER: And the other thing is with a breath test it's really hard to do cross-reactivity testing. Now first of all the actual analyte isn't the virus or other viruses. It's, you know, volatiles. And so how do you get at cross reactivity? And really the only way we could think of that's very doable and will allow developers like yourself to move forward is to test symptomatic people with a SARS test and also a respiratory panel test. Both should be authorized. There are some respiratory panels that have - and they've been authorized that have SARS on it so it would be one test. But you test, you know, a sufficient number of symptomatic people, somewhere around maybe 5% or 10%, maybe 10% of them are going to have SARS today of the symptomatic population. The rest of them are going to have some other respiratory disease, mostly viral, you know, rhino non-novel corona, et cetera, RSV, some flu, et cetera. So you should without having to test that many patients you should be able to see, you know, and a good panel that would detect most of the non-SARS viruses that are infecting patients these days and causing symptoms, you wouldn't take that many patients who are symptomatic with this kind of comparison study to show if a breath test is specific for SARS or not.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Cross-reactivity testing, Breath test for COVID, Diagnostic validation
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: What is the FDA's recommended method for conducting cross-reactivity studies for breath tests?
CLARIFIED ANSWER: The FDA suggests conducting cross-reactivity studies for breath tests by testing symptomatic people using both an authorized SARS test and an authorized respiratory panel test, ensuring sufficient representation of symptomatic patients with various respiratory diseases.
VERBATIM QUESTION: What is the FDA's recommended method for conducting cross-reactivity studies for breath tests?
VERBATIM ANSWER: And the other thing is with a breath test it's really hard to do cross-reactivity testing. Now first of all the actual analyte isn't the virus or other viruses. It's, you know, volatiles. And so how do you get at cross reactivity? And really the only way we could think of that's very doable and will allow developers like yourself to move forward is to test symptomatic people with a SARS test and also a respiratory panel test. Both should be authorized. There are some respiratory panels that have - and they've been authorized that have SARS on it so it would be one test. But you test, you know, a sufficient number of symptomatic people, somewhere around maybe 5% or 10%, maybe 10% of them are going to have SARS today of the symptomatic population. The rest of them are going to have some other respiratory disease, mostly viral, you know, rhino non-novel corona, et cetera, RSV, some flu, et cetera. So you should without having to test that many patients you should be able to see, you know, and a good panel that would detect most of the non-SARS viruses that are infecting patients these days and causing symptoms, you wouldn't take that many patients who are symptomatic with this kind of comparison study to show if a breath test is specific for SARS or not.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: cross-reactivity studies, breath tests, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: Is there a required percentage of symptomatic patients to include in cross-reactivity studies for breath tests?
CLARIFIED ANSWER: The FDA suggests that for cross-reactivity studies, 5% to 10% of symptomatic patients should be tested using a SARS test and authorized respiratory panel test to ensure specificity for SARS.
VERBATIM QUESTION: Is there a required percentage of symptomatic patients to include in cross-reactivity studies for breath tests?
VERBATIM ANSWER: And really the only way we could think of that's very doable and will allow developers like yourself to move forward is to test symptomatic people with a SARS test and also a respiratory panel test. Both should be authorized. There are some respiratory panels that have - and they've been authorized that have SARS on it so it would be one test. But you test, you know, a sufficient number of symptomatic people, somewhere around maybe 5% or 10%, maybe 10% of them are going to have SARS today of the symptomatic population. The rest of them are going to have some other respiratory disease, mostly viral, you know, rhino non-novel corona, et cetera, RSV, some flu, et cetera. So you should without having to test that many patients you should be able to see, you know, and a good panel that would detect most of the non-SARS viruses that are infecting patients these days and causing symptoms, you wouldn't take that many patients who are symptomatic with this kind of comparison study to show if a breath test is specific for SARS or not.
SPEAKER QUESTION: Anna Gozrelli
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Breath test cross-reactivity, Symptomatic patient percentage, Testing guidelines
REVIEW FLAG: False

QA Block 7-9
CLARIFIED QUESTION: Can testing a respiratory panel authorized for SARS and other viruses satisfy the cross-reactivity requirement?
CLARIFIED ANSWER: FDA suggests that testing a respiratory panel authorized for SARS and other viruses in symptomatic patients could meet cross-reactivity requirements for a breath test.
VERBATIM QUESTION: Can testing a respiratory panel authorized for SARS and other viruses satisfy the cross-reactivity requirement?
VERBATIM ANSWER: And the other thing is with a breath test it's really hard to do cross-reactivity testing. Now first of all the actual analyte isn't the virus or other viruses. It's, you know, volatiles. And so how do you get at cross reactivity? And really the only way we could think of that's very doable and will allow developers like yourself to move forward is to test symptomatic people with a SARS test and also a respiratory panel test. Both should be authorized. There are some respiratory panels that have - and they've been authorized that have SARS on it so it would be one test. But you test, you know, a sufficient number of symptomatic people, somewhere around maybe 5% or 10%, maybe 10% of them are going to have SARS today of the symptomatic population. The rest of them are going to have some other respiratory disease, mostly viral, you know, rhino non-novel corona, et cetera, RSV, some flu, et cetera. So you should without having to test that many patients you should be able to see, you know, and a good panel that would detect most of the non-SARS viruses that are infecting patients these days and causing symptoms, you wouldn't take that many patients who are symptomatic with this kind of comparison study to show if a breath test is specific for SARS or not.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Breath test specificity, Cross-reactivity, Respiratory panels
REVIEW FLAG: False


#### 8. Smartphone-Based Reader Tests: FDA Recommendations and Validation Approach

QA Block 8-1
CLARIFIED QUESTION: Does the FDA have a standardized list of hardware requirement categories for a test system that includes a smartphone, such as processor type or camera, or is it up to the test developer to provide and justify their list of requirements?
CLARIFIED ANSWER: The FDA does not provide a standardized list of hardware requirements for smartphone-based test systems. Test developers are expected to define and validate the necessary parameters based on their specific test needs and submit this information for FDA evaluation.
VERBATIM QUESTION: Does the FDA have a standardized list of hardware requirement categories for a test system that includes a smartphone, such as processor type or camera, or is it up to the test developer to provide and justify their list of requirements?
VERBATIM ANSWER: Yes I mean we take an open-minded approach and we - to this. So we don't really know what the needs of your tests are, right? You know it better than we do as far as the requirements on whatever the variables are when it comes to smart phones and cameras and image analysis. We also don't specify that you have to use a smart phone to read a test, right? But I'm trying to think if we have actually authorized a smartphone reader for SARS or anything. I don't remember that we have. So as was usual with something that's novel -- and we're totally open to it -- we learn a lot with the first developers who come to us with data and learn a lot about what our recommendations for others would be based on actual data. It's really hard to, you know, we do have a research branch in our center who could look at something like this but they aren't to my knowledge at the moment. They have so many, you know, interesting things to study but and one of those is actually digital health so or digital technology rather which is an image scanner and analysis of tissue. So they - we do have a program there and that's probably the most amenable thing that we understand relative to this. But the - there's a whole lot of variables when it comes into scanners of a rapid test, lateral flow test, you know, from what is the color of the line to the thickness of the line to the lighting to the background. And obviously different cameras or different software may impact that. So you're really the best ones to inform us based on your examination of different smart phone options and your test what's going to work best and how you define that. And then we'll look at your validation when you define those parameters and determine if that is something we can authorize.
SPEAKER QUESTION: Ling Tau
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone-based test system, hardware requirements, FDA validation
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Would you recommend reaching out directly for a more detailed conversation about a smartphone-based test system, or should we simply present the data as part of the submission?
CLARIFIED ANSWER: The FDA recommends submitting a pre-EUA with your thinking and study design for feedback, which can help prevent future issues and ensure validation plans address critical variables for smartphone-based test systems.
VERBATIM QUESTION: Would you recommend reaching out directly for a more detailed conversation about a smartphone-based test system, or should we simply present the data as part of the submission?
VERBATIM ANSWER: You know, it never hurts to send us a pre-EUA and state your thinking and study design because we may spot things that you may not think of and which would help you in your development and to prevent any hurdles later on where you might have to do some repeats so - or repeat testing. So and especially essentially novel if we can take a quick look at it and spot anything that's obvious. But as I said this is going to be, you know, new for us to know what are the variables around accurately reading a test over the smartphone and what are the important questions for us to ask in the validation plans okay?
SPEAKER QUESTION: Ling Tau
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Smartphone-based test systems, Pre-EUA recommendations, Validation considerations
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: What variables or factors should be considered during validation for smartphone-based diagnostic tests, such as lighting, line color, line thickness, or background?
CLARIFIED ANSWER: Factors to consider during validation include line color, line thickness, lighting, and background. Different cameras or software may affect results. Developers should identify the parameters that work best and submit these for FDA review.
VERBATIM QUESTION: What variables or factors should be considered during validation for smartphone-based diagnostic tests, such as lighting, line color, line thickness, or background?
VERBATIM ANSWER: But the - there's a whole lot of variables when it comes into scanners of a rapid test, lateral flow test, you know, from what is the color of the line to the thickness of the line to the lighting to the background. And obviously different cameras or different software may impact that. So you're really the best ones to inform us based on your examination of different smart phone options and your test what's going to work best and how you define that. And then we'll look at your validation when you define those parameters and determine if that is something we can authorize.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation variables, Smartphone diagnostics, Test parameters
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: Does the FDA have prior experience or authorizations for smartphone-based diagnostic test readers?
CLARIFIED ANSWER: The FDA does not recall having authorized a smartphone reader for SARS or any other test. FDA is open to novel developments and learns from data provided by the first developers to form future recommendations.
VERBATIM QUESTION: Does the FDA have prior experience or authorizations for smartphone-based diagnostic test readers?
VERBATIM ANSWER: I'm trying to think if we have actually authorized a smartphone reader for SARS or anything. I don't remember that we have. So as was usual with something that's novel -- and we're totally open to it -- we learn a lot with the first developers who come to us with data and learn a lot about what our recommendations for others would be based on actual data.
SPEAKER QUESTION: Ling Tau
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone diagnostic readers, FDA authorizations, novel device development
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: What role does the FDA's research branch play in evaluating or supporting the development of technologies like smartphone-based test readers?
CLARIFIED ANSWER: The FDA's research branch could examine smartphone-based reader development but has not engaged on this yet, focusing instead on areas like digital health and image analysis.
VERBATIM QUESTION: What role does the FDA's research branch play in evaluating or supporting the development of technologies like smartphone-based test readers?
VERBATIM ANSWER: We do have a research branch in our center who could look at something like this but they aren't to my knowledge at the moment. They have so many, you know, interesting things to study but and one of those is actually digital health so or digital technology rather which is an image scanner and analysis of tissue. So they - we do have a program there and that's probably the most amenable thing that we understand relative to this.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA research branch, Smartphone-based test readers, Digital health
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: Should test developers focus on testing specific smartphone models or software configurations to ensure accurate validation of results?
CLARIFIED ANSWER: Test developers should examine various smartphone models and configurations to determine what works best for their specific tests, as they are best suited to define the parameters. The FDA will review and validate these defined parameters.
VERBATIM QUESTION: Should test developers focus on testing specific smartphone models or software configurations to ensure accurate validation of results?
VERBATIM ANSWER: So you're really the best ones to inform us based on your examination of different smart phone options and your test what's going to work best and how you define that. And then we'll look at your validation when you define those parameters and determine if that is something we can authorize.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: smartphone models, test validation, FDA review
REVIEW FLAG: False

QA Block 8-7
CLARIFIED QUESTION: What are the FDA's expectations for defining and validating key parameters in smartphone-based diagnostic systems?
CLARIFIED ANSWER: FDA adopts an open approach, relying on developers to define parameters based on their specific test needs. Validation data will be assessed to ensure authorization suitability.
VERBATIM QUESTION: What are the FDA's expectations for defining and validating key parameters in smartphone-based diagnostic systems?
VERBATIM ANSWER: Yes I mean we take an open-minded approach and we - to this. So we don't really know what the needs of your tests are, right? You know it better than we do as far as the requirements on whatever the variables are when it comes to smart phones and cameras and image analysis. We also don't specify that you have to use a smart phone to read a test, right? But I'm trying to think if we have actually authorized a smartphone reader for SARS or anything. I don't remember that we have. So as was usual with something that's novel -- and we're totally open to it -- we learn a lot with the first developers who come to us with data and learn a lot about what our recommendations for others would be based on actual data. It's really hard to, you know, we do have a research branch in our center who could look at something like this but they aren't to my knowledge at the moment. They have so many, you know, interesting things to study but and one of those is actually digital health so or digital technology rather which is an image scanner and analysis of tissue. So they - we do have a program there and that's probably the most amenable thing that we understand relative to this. But the - there's a whole lot of variables when it comes into scanners of a rapid test, lateral flow test, you know, from what is the color of the line to the thickness of the line to the lighting to the background. And obviously different cameras or different software may impact that. So you're really the best ones to inform us based on your examination of different smart phone options and your test what's going to work best and how you define that. And then we'll look at your validation when you define those parameters and determine if that is something we can authorize.
SPEAKER QUESTION: Ling Tau
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Smartphone diagnostic systems, Validation of key parameters, FDA approach
REVIEW FLAG: False


#### 9. CDC Antigen Test Panel Testing Status Update

QA Block 9-1
CLARIFIED QUESTION: Has there been an update on the reference panel testing by the CDC for EUA authorized antigen tests?
CLARIFIED ANSWER: The CDC is nearing the start of reference panel testing but is delayed due to other missions. Alternative approaches are being considered, and developers might use certain inactivated viral strains for testing. However, preparation of these strains by BEI will take time.
VERBATIM QUESTION: Has there been an update on the reference panel testing by the CDC for EUA authorized antigen tests?
VERBATIM ANSWER: Yes, I think they're getting relatively near to starting. But, you know, the CDC is inundated with mission requests. And we are currently thinking of other options and looking into them. And we don't have what I would call a great option right now. For those developers that can utilize in their assays the various strains that have been deposited, BEI and either have been heat inactivated or perhaps more appropriately irradiated and inactivated through radiation that may be more amenable to antigen tests, you know, we're going to be reaching out. There is - we have some preliminary data within the federal government that says that irradiated SARS can be accurately detected by antigen tests. So but I don't know if that would be across the board for all antigen test developers or not if their test is sensitive to radiation of the virus or not as far as reactivity and inclusivity testing goes. But if they - it is amenable to all or most. One option is that once these strains deposited at BEI and have been inactivated by one or another method those developers that don't have BSL-3 facilities can get that material and perform the testing. So we're just working through that. The downside I'll just say to that is it takes BEI a while to inactivate virus. And obviously they don't just, you know, irradiate it or heat denature it. Then they go ahead and test it to make sure that it is non-infection or noninfectious. So it's not something that they can rush through and do. So we're hoping long- term the inactivated virus material that BEI manufacturers will be useful to this effort. So that's our current thinking as of today.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC antigen test reference panel, EUA testing updates, BEI inactivation process
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Have CDC officials started reaching out to antigen manufacturers to request samples of the product?
CLARIFIED ANSWER: The CDC is relatively near to starting outreach to antigen manufacturers, but they are inundated with mission requests and exploring other options.
VERBATIM QUESTION: Have CDC officials started reaching out to antigen manufacturers to request samples of the product?
VERBATIM ANSWER: Yes, I think they're getting relatively near to starting. But, you know, the CDC is inundated with mission requests. And we are currently thinking of other options and looking into them. And we don't have what I would call a great option right now.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC outreach to antigen manufacturers, reference panel testing, alternative options for antigen testing
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: What is the general status on the reference panel testing process?
CLARIFIED ANSWER: The FDA states that reference panel testing is nearing initiation, but the CDC faces delays due to numerous mission requests. Alternate options are being considered, including the use of irradiated SARS-CoV-2 strains, which offer promise but require validation and time for inactivation. The FDA hopes these materials can eventually support testing efforts.
VERBATIM QUESTION: What is the general status on the reference panel testing process?
VERBATIM ANSWER: Yes, I think they're getting relatively near to starting. But, you know, the CDC is inundated with mission requests. And we are currently thinking of other options and looking into them. And we don't have what I would call a great option right now. For those developers that can utilize in their assays the various strains that have been deposited, BEI and either have been heat inactivated or perhaps more appropriately irradiated and inactivated through radiation that may be more amenable to antigen tests, you know, we're going to be reaching out. There is - we have some preliminary data within the federal government that says that irradiated SARS can be accurately detected by antigen tests. So but I don't know if that would be across the board for all antigen test developers or not if their test is sensitive to radiation of the virus or not as far as reactivity and inclusivity testing goes. But if they - it is amenable to all or most. One option is that once these strains deposited at BEI and have been inactivated by one or another method those developers that don't have BSL-3 facilities can get that material and perform the testing. So we're just working through that. The downside I'll just say to that is it takes BEI a while to inactivate virus. And obviously they don't just, you know, irradiate it or heat denature it. Then they go ahead and test it to make sure that it is non-infection or noninfectious. So it's not something that they can rush through and do. So we're hoping long- term the inactivated virus material that BEI manufacturers will be useful to this effort. So that's our current thinking as of today.
SPEAKER QUESTION: Kay Taylor
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: reference panel testing, CDC progress, antigen test materials
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What are the alternatives being considered by the FDA if the CDC is unable to conduct reference panel testing as planned?
CLARIFIED ANSWER: The FDA is exploring alternatives, including using heat-inactivated or irradiated virus strains that may be more compatible with antigen tests. They are also considering making these strains available to developers without BSL-3 facilities via BEI. However, there is no clear solution at the moment.
VERBATIM QUESTION: What are the alternatives being considered by the FDA if the CDC is unable to conduct reference panel testing as planned?
VERBATIM ANSWER: We are currently thinking of other options and looking into them. And we don't have what I would call a great option right now. For those developers that can utilize in their assays the various strains that have been deposited, BEI and either have been heat inactivated or perhaps more appropriately irradiated and inactivated through radiation that may be more amenable to antigen tests, you know, we're going to be reaching out. There is - we have some preliminary data within the federal government that says that irradiated SARS can be accurately detected by antigen tests. So but I don't know if that would be across the board for all antigen test developers or not if their test is sensitive to radiation of the virus or not as far as reactivity and inclusivity testing goes. But if they - it is amenable to all or most. One option is that once these strains deposited at BEI and have been inactivated by one or another method those developers that don't have BSL-3 facilities can get that material and perform the testing. So we're just working through that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC reference panel testing, alternatives for inactivated strains, antigen test methods
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: Is irradiated SARS-CoV-2 suitable for antigen test developers to use in validating their assays?
CLARIFIED ANSWER: Irradiated SARS-CoV-2 may be suitable for some antigen test developers as preliminary data suggests it can be accurately detected, but its suitability varies depending on a test's sensitivity to viral radiation.
VERBATIM QUESTION: Is irradiated SARS-CoV-2 suitable for antigen test developers to use in validating their assays?
VERBATIM ANSWER: For those developers that can utilize in their assays the various strains that have been deposited, BEI and either have been heat inactivated or perhaps more appropriately irradiated and inactivated through radiation that may be more amenable to antigen tests, you know, we're going to be reaching out. There is - we have some preliminary data within the federal government that says that irradiated SARS can be accurately detected by antigen tests. So but I don't know if that would be across the board for all antigen test developers or not if their test is sensitive to radiation of the virus or not as far as reactivity and inclusivity testing goes.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Irradiated SARS-CoV-2, Antigen test validation, Sensitivity to viral radiation
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: What specific methods does the FDA recommend for inactivating SARS-CoV-2 strains for use in antigen testing?
CLARIFIED ANSWER: The FDA recommends heat inactivation or radiation inactivation methods for SARS-CoV-2 strains, as irradiated material has shown accurate detection in preliminary data for antigen testing.
VERBATIM QUESTION: What specific methods does the FDA recommend for inactivating SARS-CoV-2 strains for use in antigen testing?
VERBATIM ANSWER: For those developers that can utilize in their assays the various strains that have been deposited, BEI and either have been heat inactivated or perhaps more appropriately irradiated and inactivated through radiation that may be more amenable to antigen tests, you know, we're going to be reaching out. There is - we have some preliminary data within the federal government that says that irradiated SARS can be accurately detected by antigen tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: SARS-CoV-2 inactivation, antigen test preparation, radiation method
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: Can the BEI-inactivated virus materials be used by developers who lack BSL-3 facilities to perform necessary testing?
CLARIFIED ANSWER: FDA is considering using inactivated virus materials from BEI for developers without BSL-3 facilities to perform testing. However, the inactivation process by BEI takes time to ensure noninfectiousness.
VERBATIM QUESTION: Can the BEI-inactivated virus materials be used by developers who lack BSL-3 facilities to perform necessary testing?
VERBATIM ANSWER: One option is that once these strains deposited at BEI and have been inactivated by one or another method those developers that don't have BSL-3 facilities can get that material and perform the testing. So we're just working through that. The downside I'll just say to that is it takes BEI a while to inactivate virus. And obviously they don't just, you know, irradiate it or heat denature it. Then they go ahead and test it to make sure that it is non-infection or noninfectious. So it's not something that they can rush through and do. So we're hoping long- term the inactivated virus material that BEI manufacturers will be useful to this effort.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: BEI inactivated virus use, BSL-3 facility alternative, Testing challenges
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: How long does it typically take for BEI to inactivate SARS-CoV-2 and verify its non-infectious status?
CLARIFIED ANSWER: It takes BEI a significant amount of time to inactivate SARS-CoV-2, as they must also verify that the virus is rendered non-infectious, and this process cannot be expedited.
VERBATIM QUESTION: How long does it typically take for BEI to inactivate SARS-CoV-2 and verify its non-infectious status?
VERBATIM ANSWER: The downside I'll just say to that is it takes BEI a while to inactivate virus. And obviously they don't just, you know, irradiate it or heat denature it. Then they go ahead and test it to make sure that it is non-infection or noninfectious. So it's not something that they can rush through and do.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: BEI inactivation process, SARS-CoV-2, verification of non-infectious status
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: What preliminary data does the FDA have supporting the use of irradiated virus in antigen test validation?
CLARIFIED ANSWER: The FDA has preliminary data suggesting irradiated SARS-CoV-2 can be accurately detected by antigen tests, but it is unclear if this applies to all test developers or testing conditions.
VERBATIM QUESTION: What preliminary data does the FDA have supporting the use of irradiated virus in antigen test validation?
VERBATIM ANSWER: There is - we have some preliminary data within the federal government that says that irradiated SARS can be accurately detected by antigen tests. So but I don't know if that would be across the board for all antigen test developers or not if their test is sensitive to radiation of the virus or not as far as reactivity and inclusivity testing goes.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: irradiated virus, antigen tests, validation data
REVIEW FLAG: False

QA Block 9-10
CLARIFIED QUESTION: Are there potential limitations for antigen tests if the virus is treated with radiation?
CLARIFIED ANSWER: Preliminary FDA data indicates irradiated SARS can be detected accurately by antigen tests, but it's unclear if this applies to all tests, as some may not be sensitive to irradiated viruses.
VERBATIM QUESTION: Are there potential limitations for antigen tests if the virus is treated with radiation?
VERBATIM ANSWER: There is - we have some preliminary data within the federal government that says that irradiated SARS can be accurately detected by antigen tests. So but I don't know if that would be across the board for all antigen test developers or not if their test is sensitive to radiation of the virus or not as far as reactivity and inclusivity testing goes.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: radiation impact on antigen tests, SARS detection post-irradiation
REVIEW FLAG: False


#### 10. Challenges in Developing and Authorizing Antigen Tests

QA Block 10-1
CLARIFIED QUESTION: If a BSL-3 facility completes most analytical studies for an antigen test, would the FDA allow the remainder to be completed post-EUA?
CLARIFIED ANSWER: The FDA may allow the remainder of analytical studies for an antigen test to be completed post-EUA, depending on a case-by-case benefit-risk analysis.
VERBATIM QUESTION: If a BSL-3 facility completes most analytical studies for an antigen test, would the FDA allow the remainder to be completed post-EUA?
VERBATIM ANSWER: We've been flexible when it comes to authorizations and what can go into a post authorization study to fill out an application. We want to have a good sense of the performance of the assay and we very clearly allow on a case-by-case basis depending on the benefit risk calculation on the submission what we have to allow post market study to fill it out.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Post-EUA studies, Antigen test analytical studies
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Have antigen test submissions from companies using Chinese OEMs shown a pattern of failing to meet FDA requirements for home use, such as 90% sensitivity?
CLARIFIED ANSWER: Antigen tests are harder to develop and manufacture than molecular tests, which may impact their ability to meet US quality standards. Approximately two-thirds of lateral flow tests, including serology and antigen tests, are denied based on quality data.
VERBATIM QUESTION: Have antigen test submissions from companies using Chinese OEMs shown a pattern of failing to meet FDA requirements for home use, such as 90% sensitivity?
VERBATIM ANSWER: I would, you know, as far as manufacturers of antigen tests go, here is the maybe not well kept secret or maybe it is a secret that it's a lot harder to develop a good antigen test than it is to develop a good molecular test. Now, you know, I've developed both and I can tell you it's a lot easier to develop a good molecular test than a good antigen test. And it's also much easier to manufacture molecular tests then antigen tests and I've done both. So that's probably more of a factor here. Lateral flow tests and, you know, there's serology in antigen tests. I'll let you know. I mean we're declining 2/3 of serology tests that are coming, lateral flow serology tests based on NCI data, 2/3. We're only authorizing 1/3 that test at - tests performed at NCI and reviewed by the FDA. I think that's the nature or the difficulty in making really super high quality, quality high enough for the US market from the lateral flow business. And it probably is the same in antigens. I know we've denied some antigen tests. I haven't done the numbers as far as the ratio goes. But it wouldn't surprise me at all if the ratio was very similar, that it's 1/3 authorizable and 2/3 not based on data.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test performance, Chinese OEM diagnostic tests, FDA EUA submission requirements
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Is it possible for a Chinese OEM to obtain EUA for an antigen test?
CLARIFIED ANSWER: The FDA treats all foreign OEMs fairly, making EUA decisions based on data and the quality of the submission, not the country of origin, including China.
VERBATIM QUESTION: Is it possible for a Chinese OEM to obtain EUA for an antigen test?
VERBATIM ANSWER: As far as foreign OEMs we treat everybody fairly. We make decisions based on data and the quality of the submission. It doesn't matter where it comes from. And we haven't authorize that many antigen tests compared to molecular tests, but very clearly we've authorize the molecular and serology tests from many countries of the world including China. So it's not a, you know, it's not any sort of, you know, global issue that I know. So what matters is the quality of the test and the quality of the submission. That's what matters to us okay.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Chinese OEM EUA, Antigen test approvals, Submission quality
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: How difficult would it be to have three or four OEMs producing the same test for a test developer?
CLARIFIED ANSWER: The FDA allows EUA holders to expand manufacturing to new facilities without prior review. However, the test's performance at the new site must match the original.
VERBATIM QUESTION: How difficult would it be to have three or four OEMs producing the same test for a test developer?
VERBATIM ANSWER: EUA authorization holders can expand manufacturing to new plants. They don't have to - and there's no FDA review of that. We expect you to, you know, do the performance of the tests and the new manufacturing site matches the performance at the original manufacturing site but that it's not something that under EUAs that we review and make an authorization decision around.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA manufacturing policies, OEM production, Test site performance
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: What are the FDA's expectations for testing and verifying the performance of tests at new manufacturing sites?
CLARIFIED ANSWER: The FDA does not review or require authorization for expansions to new manufacturing sites under EUAs, but expects performance at new sites to be consistent with the original manufacturing site.
VERBATIM QUESTION: What are the FDA's expectations for testing and verifying the performance of tests at new manufacturing sites?
VERBATIM ANSWER: EUA authorization holders can expand manufacturing to new plants. They don't have to - and there's no FDA review of that. We expect you to, you know, do the performance of the tests and the new manufacturing site matches the performance at the original manufacturing site but that it's not something that under EUAs that we review and make an authorization decision around.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA manufacturing expansions, Performance verification, FDA review expectation
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: Are there specific challenges the FDA has observed in the development or manufacturing of high-quality antigen tests?
CLARIFIED ANSWER: The FDA notes that developing and manufacturing high-quality antigen tests is significantly more challenging than molecular tests, partly due to their inherent technical complexity and quality standards for the U.S. market. Roughly two-thirds of serology lateral flow tests do not meet required performance criteria, and the same high rejection rate likely applies to antigen tests.
VERBATIM QUESTION: Are there specific challenges the FDA has observed in the development or manufacturing of high-quality antigen tests?
VERBATIM ANSWER: I would, you know, as far as manufacturers of antigen tests go, here is the maybe not well kept secret or maybe it is a secret that it's a lot harder to develop a good antigen test than it is to develop a good molecular test. Now, you know, I've developed both and I can tell you it's a lot easier to develop a good molecular test than a good antigen test. And it's also much easier to manufacture molecular tests then antigen tests and I've done both. So that's probably more of a factor here. Lateral flow tests and, you know, there's serology in antigen tests. I'll let you know. I mean we're declining 2/3 of serology tests that are coming, lateral flow serology tests based on NCI data, 2/3. We're only authorizing 1/3 that test at - tests performed at NCI and reviewed by the FDA. I think that's the nature or the difficulty in making really super high quality, quality high enough for the US market from the lateral flow business. And it probably is the same in antigens. I know we've denied some antigen tests. I haven't done the numbers as far as the ratio goes. But it wouldn't surprise me at all if the ratio was very similar, that it's 1/3 authorizable and 2/3 not based on data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Challenges with antigen tests, Comparison to molecular tests, FDA quality standards
REVIEW FLAG: False

QA Block 10-7
CLARIFIED QUESTION: What factors contribute to the lower approval rate for lateral flow serology and antigen tests compared to molecular tests?
CLARIFIED ANSWER: The lower approval rate for lateral flow serology and antigen tests compared to molecular tests is due to the greater difficulty in developing and manufacturing high-quality lateral flow-based tests. Approximately two-thirds of serology tests fail to meet FDA requirements, and the ratio is likely similar for antigen tests.
VERBATIM QUESTION: What factors contribute to the lower approval rate for lateral flow serology and antigen tests compared to molecular tests?
VERBATIM ANSWER: I would, you know, as far as manufacturers of antigen tests go, here is the maybe not well kept secret or maybe it is a secret that it's a lot harder to develop a good antigen test than it is to develop a good molecular test. Now, you know, I've developed both and I can tell you it's a lot easier to develop a good molecular test than a good antigen test. And it's also much easier to manufacture molecular tests then antigen tests and I've done both. So that's probably more of a factor here. Lateral flow tests and, you know, there's serology in antigen tests. I'll let you know. I mean we're declining 2/3 of serology tests that are coming, lateral flow serology tests based on NCI data, 2/3. We're only authorizing 1/3 that test at - tests performed at NCI and reviewed by the FDA. I think that's the nature or the difficulty in making really super high quality, quality high enough for the US market from the lateral flow business. And it probably is the same in antigens. I know we've denied some antigen tests. I haven't done the numbers as far as the ratio goes. But it wouldn't surprise me at all if the ratio was very similar, that it's 1/3 authorizable and 2/3 not based on data.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA test approval rates, Challenges of lateral flow tests, Antigen vs molecular test development
REVIEW FLAG: False

QA Block 10-8
CLARIFIED QUESTION: Does the FDA require distinct criteria for the US market versus other global markets regarding antigen tests?
CLARIFIED ANSWER: The FDA applies the same criteria globally for antigen tests, focusing on data quality and submission quality regardless of origin.
VERBATIM QUESTION: Does the FDA require distinct criteria for the US market versus other global markets regarding antigen tests?
VERBATIM ANSWER: As far as foreign OEMs we treat everybody fairly. We make decisions based on data and the quality of the submission. It doesn't matter where it comes from. And we haven't authorize that many antigen tests compared to molecular tests, but very clearly we've authorize the molecular and serology tests from many countries of the world including China. So it's not a, you know, it's not any sort of, you know, global issue that I know. So what matters is the quality of the test and the quality of the submission. That's what matters to us okay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA review criteria, Antigen test approval, Global market standards
REVIEW FLAG: False


#### 11. UDI Requirements for EUA Tests Under Discussion

QA Block 11-1
CLARIFIED QUESTION: Are the UDI G10 requirements for Class II and higher tests applicable right now for an EUA test?
CLARIFIED ANSWER: The FDA believes that UDI G10 requirements are not applicable for Class II and higher EUA tests but recommends sending the question to the mailbox for confirmation.
VERBATIM QUESTION: Are the UDI G10 requirements for Class II and higher tests applicable right now for an EUA test?
VERBATIM ANSWER: I believe they are not applicable. Toby do you know? I believe that is the case. It would probably be best if you can send that question in to the mailbox so that we can confirm but I'm pretty sure that they are not applicable.
SPEAKER QUESTION: Christopher Benson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: UDI G10 requirements, EUA tests, Regulatory clarification
REVIEW FLAG: True

QA Block 11-3
CLARIFIED QUESTION: Will the FDA add information about UDI requirements for EUA tests to the Frequently Asked Questions page?
CLARIFIED ANSWER: The FDA will review this issue and provide a definitive answer on the UDI requirements for EUA tests in the next town hall. They may also consider updating the Frequently Asked Questions page.
VERBATIM QUESTION: Will the FDA add information about UDI requirements for EUA tests to the Frequently Asked Questions page?
VERBATIM ANSWER: Let's find that out and provide that definitive answer on the next town hall call and consider whether or not we put it on the Frequently Asked Questions page.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: UDI requirements, EUA tests, FDA FAQ page
REVIEW FLAG: False


#### 12. Reporting and Risk Mitigation for At-Home Antigen Testing

QA Block 12-1
CLARIFIED QUESTION: What guidance is available for reporting personal and user data for at-home COVID-19 tests using a mobile app?
CLARIFIED ANSWER: The FDA acknowledges challenges in establishing effective reporting methods for at-home COVID-19 test data while ensuring HIPAA compliance. Guidance is evolving, and a chief medical officer at HHS is addressing the issue. Developers can email the templates email address to reach Dr. Sara Brenner for further guidance.
VERBATIM QUESTION: What guidance is available for reporting personal and user data for at-home COVID-19 tests using a mobile app?
VERBATIM ANSWER: and mindful of HIPAA requirements. And those are all really important questions. And the, you know, the facts are that we are still struggling with how to do that reporting well. Even if you have an app to report to connecting it to the database and getting authorizations from all of the states, you know, and the federal government to be able to do that and connect it all up report results that is a mission in process. And we're fortunate to have our office, the office I lead is a chief medical officer who is an expert in this, Dr. Sara Brenner who's actually on loan right now to HHS to work primarily on this reporting question. And it's - I know that there's Web sites and there's documents that are available but I don't have them at my fingertips, Sara would. It's probably something Toby and Irene that we want to add to our slide deck that we provide at the town hall, some materials around our reporting and since we've had a number of questions about reporting and those links to important documents that can guide developers. But we're very interested in working with you. So if you send us an email to the templates email address and you ask for that to be forward into Dr. Sara Brenner, B-R-E-N-N-E-R, Sara will get back to you with as much as she can tell you about the process now.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: At-home COVID-19 test reporting, Mobile app data confidentiality, HIPAA compliance
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Is it necessary to include a mechanism in the app to estimate the prevalence in the consumer's region to provide indications on positive and negative predictive value for the test results?
CLARIFIED ANSWER: FDA recognizes that a consumer's region prevalence could affect PPV and NPV, but implementing such a mechanism would require precise and up-to-date data, as well as an adaptable system with a geo-locator feature. Developers can propose this in a pre-EUA or EUA submission.
VERBATIM QUESTION: Is it necessary to include a mechanism in the app to estimate the prevalence in the consumer's region to provide indications on positive and negative predictive value for the test results?
VERBATIM ANSWER: It's an interesting question. Certainly in a low prevalence population your risk - your PPV is going to go down, your Positive Predictive Value's going to go down but your NPV is going to go up. But we've heard that false positives with antigen tests especially in point-of-care congregant settings where then they move a patient based on their test results into a COVID ward can expose someone who doesn't really have COVID to SARS and developing COVID. So it's a complex thing. The other thing is and obviously if you're prevalence is higher then it's kind of the reverse. But, you know, one of the challenges with that is you'd have to have - first of all you'd have to have, you know, even to consider it you'd have to have really good prevalence data and up to the minute prevalence data which we don't have. And then you'd have to have an adaptable system that had some geo-locator that says well you're in this ZIP Code and this is the prevalence and so this is the number to use, you know, for your mitigation. So it's an interesting idea and I don't want to give you any more definitive - I don't want to give you any definitive answer on it. We're always open to new ideas. So if you want to propose this in a pre-EUA or an EUA as the mitigation please do. I can't guarantee the results. But like I said, you know, this town hall is to help educate folks about our current thinking. But we learn just as much from developers, you know, as you do from us. So, you know, thanks for asking a creative question.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Prevalence in diagnostics, Positive and Negative Predictive Values, COVID-19 testing apps
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: Does the FDA consider the prediction of COVID-19 prevalence in the app user's region as a risk mitigation factor for prescription-based COVID-19 tests?
CLARIFIED ANSWER: FDA notes that predicting COVID-19 prevalence in a region could be considered, but challenges such as the lack of accurate, up-to-date prevalence data and the need for adaptable systems with geo-location exist. They do not have a definitive stance but are open to proposals.
VERBATIM QUESTION: Does the FDA consider the prediction of COVID-19 prevalence in the app user's region as a risk mitigation factor for prescription-based COVID-19 tests?
VERBATIM ANSWER: It's an interesting question. Certainly in a low prevalence population your risk - your PPV is going to go down, your Positive Predictive Value's going to go down but your NPV is going to go up. But we've heard that false positives with antigen tests especially in point-of-care congregant settings where then they move a patient based on their test results into a COVID ward can expose someone who doesn't really have COVID to SARS and developing COVID. So it's a complex thing. The other thing is and obviously if you're prevalence is higher then it's kind of the reverse. But, you know, one of the challenges with that is you'd have to have - first of all you'd have to have, you know, even to consider it you'd have to have really good prevalence data and up to the minute prevalence data which we don't have. And then you'd have to have an adaptable system that had some geo-locator that says well you're in this ZIP Code and this is the prevalence and so this is the number to use, you know, for your mitigation. So it's an interesting idea and I don't want to give you any more definitive - I don't want to give you any definitive answer on it. We're always open to new ideas.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 prevalence, Risk mitigation, Diagnostic apps
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: How can an app comply with HIPAA requirements when reporting COVID-19 test results?
CLARIFIED ANSWER: The FDA acknowledges challenges around ensuring HIPAA compliance in COVID-19 result reporting through apps, emphasizing that it is an ongoing process. Developers are encouraged to contact FDA via the templates email to connect with experts like Dr. Sara Brenner for resources and guidance.
VERBATIM QUESTION: How can an app comply with HIPAA requirements when reporting COVID-19 test results?
VERBATIM ANSWER: And those are all really important questions. And the, you know, the facts are that we are still struggling with how to do that reporting well. Even if you have an app to report to connecting it to the database and getting authorizations from all of the states, you know, and the federal government to be able to do that and connect it all up report results that is a mission in process. Andwe're fortunate to have our office, the office I lead is a chief medical officer who is an expert in this, Dr. Sara Brenner who's actually on loan right now to HHS to work primarily on this reporting question. And it's - I know that there's Web sites and there's documents that are available but I don't have them at my fingertips, Sara would. It's probably something Toby and Irene that we want to add to our slide deck that we provide at the town hall, some materials around our reporting and since we've had a number of questions about reporting and those links to important documents that can guide developers. But we're very interested in working with you. So if you send us an email to the templates email address and you ask for that to be forward into Dr. Sara Brenner, B-R-E-N-N-E-R, Sara will get back to you with as much as she can tell you about the process now.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: HIPAA compliance, COVID-19 reporting, Mobile app guidance
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: What challenges should developers expect when trying to obtain state and federal authorizations for reporting COVID-19 test results from a mobile app?
CLARIFIED ANSWER: FDA is still working on how to achieve effective reporting from apps. Developers will face challenges in connecting their apps to databases and obtaining state and federal authorizations to report results.
VERBATIM QUESTION: What challenges should developers expect when trying to obtain state and federal authorizations for reporting COVID-19 test results from a mobile app?
VERBATIM ANSWER: and mindful of HIPAA requirements. And those are all really important questions. And the, you know, the facts are that we are still struggling with how to do that reporting well. Even if you have an app to report to connecting it to the database and getting authorizations from all of the states, you know, and the federal government to be able to do that and connect it all up report results that is a mission in process.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Reporting challenges, COVID-19 test results, State and federal authorizations
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: What data connectivity considerations exist for linking a reporting app to state and federal databases?
CLARIFIED ANSWER: Establishing connectivity between a reporting app and state or federal databases is challenging and requires authorizations from all states and the federal government. This process is still under development.
VERBATIM QUESTION: What data connectivity considerations exist for linking a reporting app to state and federal databases?
VERBATIM ANSWER: And the, you know, the facts are that we are still struggling with how to do that reporting well. Even if you have an app to report to connecting it to the database and getting authorizations from all of the states, you know, and the federal government to be able to do that and connect it all up report results that is a mission in process. And
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: data reporting, app connectivity, state and federal database integration
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: Can the FDA provide links to online resources or documents that outline recommendations for reporting COVID-19 test results?
CLARIFIED ANSWER: The FDA indicates the existence of websites and documents with guidance on COVID-19 test reporting, but they are not readily accessible. Developers can request specific information by emailing the FDA's templates email address to connect with Dr. Sara Brenner, who specializes in this topic.
VERBATIM QUESTION: Can the FDA provide links to online resources or documents that outline recommendations for reporting COVID-19 test results?
VERBATIM ANSWER: And those are all really important questions. And the, you know, the facts are that we are still struggling with how to do that reporting well. Even if you have an app to report to connecting it to the database and getting authorizations from all of the states, you know, and the federal government to be able to do that and connect it all up report results that is a mission in process. Andwe're fortunate to have our office, the office I lead is a chief medical officer who is an expert in this, Dr. Sara Brenner who's actually on loan right now to HHS to work primarily on this reporting question. And it's - I know that there's Web sites and there's documents that are available but I don't have them at my fingertips, Sara would. It's probably something Toby and Irene that we want to add to our slide deck that we provide at the town hall, some materials around our reporting and since we've had a number of questions about reporting and those links to important documents that can guide developers. But we're very interested in working with you. So if you send us an email to the templates email address and you ask for that to be forward into Dr. Sara Brenner, B-R-E-N-N-E-R, Sara will get back to you with as much as she can tell you about the process now.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 test reporting, Recommendations or documents, Access through FDA email
REVIEW FLAG: False

QA Block 12-8
CLARIFIED QUESTION: Is it feasible to use geo-located prevalence data to adjust the interpretation of antigen test results within an app?
CLARIFIED ANSWER: Using geo-located prevalence data to adjust antigen test interpretation raises challenges such as the need for accurate, up-to-the-minute prevalence data and adaptable systems with geo-locators. The FDA welcomes new ideas but cannot yet provide a definitive answer.
VERBATIM QUESTION: Is it feasible to use geo-located prevalence data to adjust the interpretation of antigen test results within an app?
VERBATIM ANSWER: It's an interesting question. Certainly in a low prevalence population your risk - your PPV is going to go down, your Positive Predictive Value's going to go down but your NPV is going to go up. But we've heard that false positives with antigen tests especially in point-of-care congregant settings where then they move a patient based on their test results into a COVID ward can expose someone who doesn't really have COVID to SARS and developing COVID. So it's a complex thing. The other thing is and obviously if you're prevalence is higher then it's kind of the reverse. But, you know, one of the challenges with that is you'd have to have - first of all you'd have to have, you know, even to consider it you'd have to have really good prevalence data and up to the minute prevalence data which we don't have. And then you'd have to have an adaptable system that had some geo-locator that says well you're in this ZIP Code and this is the prevalence and so this is the number to use, you know, for your mitigation. So it's an interesting idea and I don't want to give you any more definitive - I don't want to give you any definitive answer on it. We're always open to new ideas.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Geo-located prevalence data, Antigen test interpretation, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 12-9
CLARIFIED QUESTION: What prerequisites are necessary to implement prevalence-based risk mitigation in a diagnostic app?
CLARIFIED ANSWER: To implement prevalence-based risk mitigation, reliable and up-to-date prevalence data is needed along with an adaptable system capable of using geo-location to assess regional prevalence for risk adjustment.
VERBATIM QUESTION: What prerequisites are necessary to implement prevalence-based risk mitigation in a diagnostic app?
VERBATIM ANSWER: But, you know, one of the challenges with that is you'd have to have - first of all you'd have to have, you know, even to consider it you'd have to have really good prevalence data and up to the minute prevalence data which we don't have. And then you'd have to have an adaptable system that had some geo-locator that says well you're in this ZIP Code and this is the prevalence and so this is the number to use, you know, for your mitigation.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: prevalence-based risk mitigation, diagnostic app development, data requirements
REVIEW FLAG: False

QA Block 12-10
CLARIFIED QUESTION: How can prevalence data be integrated into a system in real-time to ensure proper mitigation of risk in test result interpretation?
CLARIFIED ANSWER: Integrating real-time prevalence data to mitigate risk in test result interpretation is complex. It would require accurate, up-to-date data and adaptable systems with geo-location. Currently, such an approach is not definitive or established, though the FDA is open to proposals.
VERBATIM QUESTION: How can prevalence data be integrated into a system in real-time to ensure proper mitigation of risk in test result interpretation?
VERBATIM ANSWER: It's an interesting question. Certainly in a low prevalence population your risk - your PPV is going to go down, your Positive Predictive Value's going to go down but your NPV is going to go up. But we've heard that false positives with antigen tests especially in point-of-care congregant settings where then they move a patient based on their test results into a COVID ward can expose someone who doesn't really have COVID to SARS and developing COVID. So it's a complex thing. The other thing is and obviously if you're prevalence is higher then it's kind of the reverse. But, you know, one of the challenges with that is you'd have to have - first of all you'd have to have, you know, even to consider it you'd have to have really good prevalence data and up to the minute prevalence data which we don't have. And then you'd have to have an adaptable system that had some geo-locator that says well you're in this ZIP Code and this is the prevalence and so this is the number to use, you know, for your mitigation. So it's an interesting idea and I don't want to give you any more definitive - I don't want to give you any definitive answer on it. We're always open to new ideas.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Prevalence data, Risk mitigation, COVID-19 test interpretation
REVIEW FLAG: False

QA Block 12-11
CLARIFIED QUESTION: Would the FDA accommodate creative or novel mitigation proposals incorporating COVID-19 prevalence data through the pre-EUA or EUA process?
CLARIFIED ANSWER: The FDA is open to reviewing novel mitigation proposals incorporating COVID-19 prevalence data through the pre-EUA or EUA process but cannot guarantee outcomes.
VERBATIM QUESTION: Would the FDA accommodate creative or novel mitigation proposals incorporating COVID-19 prevalence data through the pre-EUA or EUA process?
VERBATIM ANSWER: So if you want to propose this in a pre-EUA or an EUA as the mitigation please do. I can't guarantee the results. But like I said, you know, this town hall is to help educate folks about our current thinking. But we learn just as much from developers, you know, as you do from us. So, you know, thanks for asking a creative question.
SPEAKER QUESTION: Gloria
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA process, COVID-19 prevalence data, mitigation proposals
REVIEW FLAG: False


#### 13. Differentiating Diagnostic, Screening, and Surveillance COVID-19 Testing

QA Block 13-1
CLARIFIED QUESTION: Is there any issue with using already distributed antigen tests for our organization's surveillance testing?
CLARIFIED ANSWER: The FDA does not regulate surveillance testing. Antigen tests are typically single-use for individual patients, making them challenging to use for surveillance testing, which is population-based and often involves pooling. In case of a positive pool, individuals should be directed for further testing in CLIA labs.
VERBATIM QUESTION: Is there any issue with using already distributed antigen tests for our organization's surveillance testing?
VERBATIM ANSWER: So well yes so it's a bit complicated. So first of all the FDA has tried to provide some clarity on this on our FAQs with regard to what is diagnostic testing what is screening, asymptomatic screening testing...and what is surveillance testing and has clearly said that for COVID-19 at least the FDA is not going to be regulating surveillance testing. So but one of the challenges which you mentioned with the antigen test is it's a single use for typically for a single patient. And it's hard to do purely surveillance testing when you have one patient and one result and it's right there in the patient sees the result or is the test itself. So that isn't, you know, when a patient gets a results back or an employee gets the results back that tells them that their positive or negative that is not what we would typically think of it as surveillance testing. Surveillance testing is population-based. Typically it uses pooling. And then if you have a positive pool at least the FDA current thinking on this, is that if it's positive pool you can say to that pool of people, go get a CLIA lab test and get a results. And so the negative people you can say you're negative but you don't direct them to get it. You don't direct them to get a CLIA test.
SPEAKER QUESTION: Mac Clement
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Use of antigen tests, Surveillance testing criteria, Regulatory guidance
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: What does the FDA consider to be the difference between diagnostic and surveillance testing?
CLARIFIED ANSWER: The FDA distinguishes surveillance testing as population-based with pooling, whereas diagnostic testing typically focuses on individual patients and single-use results. Diagnostic tests determine whether an individual is positive or negative; surveillance testing informs broader population health trends without individual clinical decisions.
VERBATIM QUESTION: What does the FDA consider to be the difference between diagnostic and surveillance testing?
VERBATIM ANSWER: The FDA has tried to provide some clarity on this on our FAQs with regard to what is diagnostic testing what is screening, asymptomatic screening testing and what is surveillance testing and has clearly said that for COVID-19 at least the FDA is not going to be regulating surveillance testing. So but one of the challenges which you mentioned with the antigen test is it's a single use for typically for a single patient. And it's hard to do purely surveillance testing when you have one patient and one result and it's right there in the patient sees the result or is the test itself. So that isn't, you know, when a patient gets a results back or an employee gets the results back that tells them that their positive or negative that is not what we would typically think of it as surveillance testing. Surveillance testing is population-based. Typically it uses pooling. And then if you have a positive pool at least the FDA current thinking on this, is that if it's positive pool you can say to that pool of people, go get a CLIA lab test and get a results. And so the negative people you can say you're negative but you don't direct them to get it. You don't direct them to get a CLIA test.
SPEAKER QUESTION: Mac Clement
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Diagnostic vs surveillance testing, FDA testing definitions, Pooling in surveillance
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: Does the FDA provide guidelines for conducting surveillance testing with antigen tests?
CLARIFIED ANSWER: The FDA does not regulate surveillance testing for COVID-19. Surveillance testing is considered population-based and may involve pooling samples, unlike antigen tests which are generally for individual use.
VERBATIM QUESTION: Does the FDA provide guidelines for conducting surveillance testing with antigen tests?
VERBATIM ANSWER: The FDA has tried to provide some clarity on this on our FAQs with regard to what is diagnostic testing what is screening, asymptomatic screening testing and what is surveillance testing and has clearly said that for COVID-19 at least the FDA is not going to be regulating surveillance testing. So but one of the challenges which you mentioned with the antigen test is it's a single use for typically for a single patient. And it's hard to do purely surveillance testing when you have one patient and one result and it's right there in the patient sees the result or is the test itself. So that isn't, you know, when a patient gets a results back or an employee gets the results back that tells them that their positive or negative that is not what we would typically think of it as surveillance testing. Surveillance testing is population-based. Typically it uses pooling. And then if you have a positive pool at least the FDA current thinking on this, is that if it's positive pool you can say to that pool of people, go get a CLIA lab test and get a results. And so the negative people you can say you're negative but you don't direct them to get it. You don't direct them to get a CLIA test.
SPEAKER QUESTION: Mac Clement
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Surveillance testing, FDA guidelines, Use of antigen tests
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: Is pooling required for surveillance testing according to the FDA's guidelines?
CLARIFIED ANSWER: The FDA considers pooling a typical method for surveillance testing, where a positive pool leads to recommendations for individual CLIA lab testing.
VERBATIM QUESTION: Is pooling required for surveillance testing according to the FDA's guidelines?
VERBATIM ANSWER: Surveillance testing is population-based. Typically it uses pooling. And then if you have a positive pool at least the FDA current thinking on this, is that if it's positive pool you can say to that pool of people, go get a CLIA lab test and get a results.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: surveillance testing, pooling, FDA guidelines
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: Can surveillance testing results be used to directly inform individuals of their infection status?
CLARIFIED ANSWER: Surveillance testing results are not typically used to directly inform individuals of their infection status; such tests are not intended to provide individual diagnostic results.
VERBATIM QUESTION: Can surveillance testing results be used to directly inform individuals of their infection status?
VERBATIM ANSWER: And it's hard to do purely surveillance testing when you have one patient and one result and it's right there in the patient sees the result or is the test itself. So that isn't, you know, when a patient gets a results back or an employee gets the results back that tells them that their positive or negative that is not what we would typically think of it as surveillance testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: surveillance testing, diagnostic utility, individual infection status
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: What is the FDA's current stance on follow-up testing for individuals in a positive pool from surveillance testing?
CLARIFIED ANSWER: The FDA currently suggests that individuals in a positive pool from surveillance testing should get follow-up testing at a CLIA lab. Those in the negative pool do not need follow-up testing.
VERBATIM QUESTION: What is the FDA's current stance on follow-up testing for individuals in a positive pool from surveillance testing?
VERBATIM ANSWER: Surveillance testing is population-based. Typically it uses pooling. And then if you have a positive pool at least the FDA current thinking on this, is that if it's positive pool you can say to that pool of people, go get a CLIA lab test and get a results. And so the negative people you can say you're negative but you don't direct them to get it. You don't direct them to get a CLIA test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: surveillance testing, pooling, follow-up testing
REVIEW FLAG: False


#### 14. Usability Study Requirements for Point-of-Care Molecular Tests

QA Block 14-1
CLARIFIED QUESTION: What are the requirements of a usability study for a molecular point-of-care claim?
CLARIFIED ANSWER: The FDA does not require an additional usability study for molecular point-of-care claims. The usability aspects are incorporated into the clinical study to streamline the process.
VERBATIM QUESTION: What are the requirements of a usability study for a molecular point-of-care claim?
VERBATIM ANSWER: Not for point-of-care. ...into the discussion, the clinical study so that it would streamline things for you.
SPEAKER QUESTION: Rainer Ziermann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Usability study requirements, Molecular point-of-care claims, Clinical study integration
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: For a point-of-care molecular test, should we include 30 participants in the human usability study as per the guidance?
CLARIFIED ANSWER: For point-of-care molecular tests, an additional usability study involving 30 participants is not required as this has been integrated into the clinical study.
VERBATIM QUESTION: For a point-of-care molecular test, should we include 30 participants in the human usability study as per the guidance?
VERBATIM ANSWER: Not for point-of-care. No I believe we've built that...into the discussion, the clinical study so that it would streamline things for you.
SPEAKER QUESTION: Rainer Ziermann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care molecular tests, Usability study requirements, Clinical study integration
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: Are we required to do an additional usability study beyond the clinical study for a molecular point-of-care test?
CLARIFIED ANSWER: An additional usability study beyond the clinical study is not required for a molecular point-of-care test.
VERBATIM QUESTION: Are we required to do an additional usability study beyond the clinical study for a molecular point-of-care test?
VERBATIM ANSWER: Not for point-of-care.
SPEAKER QUESTION: Rainer Ziermann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Usability study requirements, Point-of-care molecular test, Submission requirements
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: What are the expectations for validating point-of-care tests in multiple clinics?
CLARIFIED ANSWER: FDA recommends including 30 positives for clinical study validation and prefers testing across more than one clinic. Additionally, involving five to six different users is suggested, but testing in multiple clinics is not a formal requirement.
VERBATIM QUESTION: What are the expectations for validating point-of-care tests in multiple clinics?
VERBATIM ANSWER: We have 30 positives for the point-of-care clinical study validation. And then we do want to see - it would be great to see more than one clinic although I don't think that's a formal requirement. But we do like to see five to six different people if I remember correctly from the template, perform the test and not just, you know, one person in one clinic performing the test.
SPEAKER QUESTION: Rainer Ziermann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care test validation, Multi-clinic testing, Participant requirements
REVIEW FLAG: False

QA Block 14-6
CLARIFIED QUESTION: Do usability studies for point-of-care molecular tests require five to six different operators performing the test?
CLARIFIED ANSWER: FDA prefers to see five to six different operators perform the test for point-of-care molecular tests rather than having it performed by just one person in a single clinic.
VERBATIM QUESTION: Do usability studies for point-of-care molecular tests require five to six different operators performing the test?
VERBATIM ANSWER: But we do like to see five to six different people if I remember correctly from the template, perform the test and not just, you know, one person in one clinic performing the test.
SPEAKER QUESTION: Rainer Ziermann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability studies, point-of-care tests, number of operators
REVIEW FLAG: False

QA Block 14-7
CLARIFIED QUESTION: Are there differences in user study requirements between point-of-care and home-based (OTC or prescription) molecular tests?
CLARIFIED ANSWER: For home-based (OTC or prescription) molecular tests, user study requirements are larger and clearer compared to point-of-care molecular tests.
VERBATIM QUESTION: Are there differences in user study requirements between point-of-care and home-based (OTC or prescription) molecular tests?
VERBATIM ANSWER: If you move into the home setting either OTC or Rx then we ask for clear user studies and the numbers are bigger for that.
SPEAKER QUESTION: Rainer Ziermann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: user study requirements, point-of-care tests, home-based molecular tests
REVIEW FLAG: False

QA Block 14-8
CLARIFIED QUESTION: Should clinical study design for point-of-care tests incorporate usability elements to streamline submission?
CLARIFIED ANSWER: The FDA indicates that usability elements are integrated into the clinical study for point-of-care tests to streamline submissions, with no additional usability study required.
VERBATIM QUESTION: Should clinical study design for point-of-care tests incorporate usability elements to streamline submission?
VERBATIM ANSWER: No I believe we've built that We've got... ...into the discussion, the clinical study so that it would streamline things for you.
SPEAKER QUESTION: Rainer Ziermann
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical study design, usability study requirements, streamlining submissions
REVIEW FLAG: False

### removed qa blocks
QA Block 6-2
CLARIFIED QUESTION: If a manufacturer validates their kit for NP swabs, do they also need to include anterior nasal swab testing in the validation for antigen tests?
CLARIFIED ANSWER: FDA requires validation with patient data for anterior nasal swabs for antigen tests due to differences in viral loads. Validation for anterior nasal or mid-turbinate swabs is encouraged, as they are better tolerated and more practical for self-collection and home use.
VERBATIM QUESTION: If a manufacturer validates their kit for NP swabs, do they also need to include anterior nasal swab testing in the validation for antigen tests?
VERBATIM ANSWER: Yes to talk specifically about the antigen test yes we would ask to see patient data for anterior nasal swab. And the antigen tests are less sensitive. They're more sensitive to differences in viral loads that might happen between the nasopharynx and the anterior. So and it's important to understand that performance difference. Now we're not requiring for an antigen test that they do a nasopharyngeal swab. A matter of fact I encourage most to try to validate and get their recommended sensitivity with anterior nares or, you know, worst-case mid-turbinate swabs because those are much better tolerated. They can be if you validate it for self-collection they can be self-collected. They are then amenable if you have a good antigen test and it's easy to use for home use either prescription or over-the-counter. So, you know, whereas, you know, a consumer cannot perform nasopharyngeal swab on themselves, at least not safely.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test validation, anterior nasal swabs, self-collection feasibility
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: What is the FDA's position on using anterior nasal swabs for antigen test validation instead of nasopharyngeal swabs?
CLARIFIED ANSWER: The FDA prefers validation of antigen tests using anterior nasal swabs due to better tolerability and potential for self-collection, as well as their relevance for at-home testing. Nasopharyngeal swabs are not required for antigen test validation.
VERBATIM QUESTION: What is the FDA's position on using anterior nasal swabs for antigen test validation instead of nasopharyngeal swabs?
VERBATIM ANSWER: Yes to talk specifically about the antigen test yes we would ask to see patient data for anterior nasal swab. And the antigen tests are less sensitive. They're more sensitive to differences in viral loads that might happen between the nasopharynx and the anterior. So and it's important to understand that performance difference. Now we're not requiring for an antigen test that they do a nasopharyngeal swab. A matter of fact I encourage most to try to validate and get their recommended sensitivity with anterior nares or, you know, worst-case mid- turbinate swabs because those are much better tolerated. They can be if you validate it for self-collection they can be self-collected. They are then amenable if you have a good antigen test and it's easy to use for home use either prescription or over-the-counter. So, you know, whereas, you know, a consumer cannot perform nasopharyngeal swab on them selves, at least not safely.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test validation, anterior nasal swabs, nasopharyngeal swabs
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: Does the FDA require manufacturers to validate antigen tests for nasopharyngeal swabs if validating for anterior nasal swabs?
CLARIFIED ANSWER: The FDA does not require manufacturers to validate antigen tests for nasopharyngeal swabs if validating for anterior nasal swabs, but validation with patient data for anterior nasal swabs is required due to potential differences in viral loads.
VERBATIM QUESTION: Does the FDA require manufacturers to validate antigen tests for nasopharyngeal swabs if validating for anterior nasal swabs?
VERBATIM ANSWER: Yes to talk specifically about the antigen test yes we would ask to see patient data for anterior nasal swab. And the antigen tests are less sensitive. They're more sensitive to differences in viral loads that might happen between the nasopharynx and the anterior. So and it's important to understand that performance difference. Now we're not requiring for an antigen test that they do a nasopharyngeal swab. A matter of fact I encourage most to try to validate and get their recommended sensitivity with anterior nares or, you know, worst-case mid- turbinate swabs because those are much better tolerated. They can be if you validate it for self-collection they can be self-collected. They are then amenable if you have a good antigen test and it's easy to use for home use either prescription or over-the-counter. So, you know, whereas, you know, a consumer cannot perform nasopharyngeal swab on them selves, at least not safely.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test validation, anterior nasal swab, nasopharyngeal swab
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: Why does the FDA recommend targeting asymptomatic populations specifically for novel breath tests?
CLARIFIED ANSWER: The FDA recommends targeting asymptomatic populations for novel breath tests because the benefit-risk balance favors aiding in pandemic control by identifying positive cases in individuals who may spread the disease unknowingly. High sensitivity in asymptomatic cases is crucial for these devices.
VERBATIM QUESTION: Why does the FDA recommend targeting asymptomatic populations specifically for novel breath tests?
VERBATIM ANSWER: Yes we do. I can give you some of our current thinking and philosophy as it comes to breath test. This is all still being developed so I wouldn't - but I think our team can provide you with even more specifics if you sent an email to the templates email mailbox. But I want to point you in sort of the flavor of where we're going here so you understand and can ask good questions hopefully. One is when you think about the benefit risk of a breath test and in aiding in this pandemic, you know, if somebody is symptomatic versus somebody who is asymptomatic, the benefit risk favors testing the asymptomatic populations with a novel device such as this, especially if it has a high sensitivity in the asymptomatic population. You know, if someone's symptomatic and it's a totally novel device when they're, you know, when they're, you know, when the concern about finding positive people is more moving into the asymptomatic population now as we try to control the spread of disease. If someone's symptomatic they should be isolating, you know, and masking and all those things and get tests but if the tests don't make sense then. So the benefit risk really favors using the breath test in the asymptomatic population. We would want to see that, you know, it has a relatively high sensitivity in asymptomatic population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic populations, breath test sensitivity, benefit-risk analysis
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: When will the FDA confirm whether UDI G10 requirements are applicable to EUA tests?
CLARIFIED ANSWER: FDA plans to confirm the applicability of UDI G10 requirements for EUA tests during the next town hall and may add the information to the FAQ page.
VERBATIM QUESTION: When will the FDA confirm whether UDI G10 requirements are applicable to EUA tests?
VERBATIM ANSWER: Let's find that out and provide that definitive answer on the next town hall call and consider whether or not we put it on the Frequently Asked Questions page.
SPEAKER QUESTION: Christopher Benson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: UDI G10 requirements, EUA tests, Future confirmation
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: What is the scope required for a usability study to support a point-of-care claim?
CLARIFIED ANSWER: A separate usability study is not required for a molecular point-of-care claim, as it is integrated into the clinical evaluation.
VERBATIM QUESTION: What is the scope required for a usability study to support a point-of-care claim?
VERBATIM ANSWER: Not for point-of-care.
SPEAKER QUESTION: Rainer Ziermann
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability study, point-of-care diagnostics, submission requirements
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 09:56:59 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 14
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What types of decisions related to EUAs are being counted in the FDA's daily metrics?
QI 1-2: How can developers identify updates to their existing EUA authorizations on the FDA website?
QI 1-3: Are all decisions made by the FDA about COVID-19 test EUAs publicly disclosed?
QI 1-4: Why are some negative decisions or pre-EUA closeouts not publicized?
QI 1-5: What is the current processing capacity of the FDA in handling new EUA applications compared to the start of the pandemic?

#### Section 2 of 14
##### Explicit Questions Extraction
QE 2-1: What is FDA's current thinking about whether acceptable performance from a clinical study with one representative iPhone model could allow other mobile phone models and operating systems meeting the initial set of critical smartphone specifications to be considered acceptable for use as alternative devices?
QE 2-2: Does FDA prefer a stepwise approach for manufacturers regarding smartphone models and operating systems?
QE 2-3: Is this for reporting purposes only or to capture and analyze an image of a device to make a positive or negative call?

##### Implicit Questions Extraction
QI 2-1: What are the criteria for determining the accuracy and reliability of a smartphone used to capture and analyze diagnostic test images?
QI 2-2: Can a comparison study between smartphone models be used instead of a full clinical study to validate additional phone models?
QI 2-3: Are there defined risks the FDA evaluates when reviewing smartphones not included in a clinical study for diagnostic tests?
QI 2-4: What type of data might the FDA request to support the inclusion of additional smartphone models or manufacturers for a diagnostic test?
QI 2-5: Does the inclusion of a reporting feature in a mobile diagnostic app impact the EUA authorization process?

#### Section 3 of 14
##### Explicit Questions Extraction
QE 3-1: What is the FDA's current thinking on PCR versus antigen tests and when they could be optimally used?
QE 3-2: Why is FDA still issuing EUAs that require a prescription for a test when there is a desperate need for mass testing?
QE 3-3: Does the FDA still maintain that there is a higher chance of false negatives for antigen tests compared to molecular tests?

##### Implicit Questions Extraction
QI 3-1: What additional validation work is required to obtain over-the-counter (OTC) authorization for a test?
QI 3-2: Are there specific strengths and weaknesses of central lab antigen testing versus central lab molecular testing that developers should consider?
QI 3-3: How does the FDA view the trade-offs between the sensitivity of molecular tests and the situational usefulness of antigen tests?
QI 3-4: Does the FDA provide specific labeling requirements for antigen test results, such as presumed negative warnings?
QI 3-5: Are there technological challenges unique to creating point-of-care or home-use molecular tests compared to antigen tests?
QI 3-6: What considerations determine whether a test is waived or deemed waived for point-of-care use?
QI 3-7: Is the FDA monitoring production scalability when authorizing antigen tests, and if so, how does it evaluate this capability?

#### Section 4 of 14
##### Explicit Questions Extraction
QE 4-1: What are the agency's expectations around system validation or updating after major updates to a smartphone operating system?

##### Implicit Questions Extraction
QI 4-1: What steps should a test developer take to monitor smartphone operating system updates?
QI 4-2: Does the FDA expect test developers to establish relationships with smartphone manufacturers to anticipate system updates?
QI 4-3: What should a test developer do if an operating system update negatively impacts test performance?
QI 4-4: How can developers incorporate plans for handling operating system updates into their EUA submissions?
QI 4-5: What is the FDA's guidance on building change control procedures into EUA applications for addressing periodic operating system updates?

#### Section 5 of 14
##### Explicit Questions Extraction
QE 5-1: If a test developer wishes to seek a sample pooling claim for the SARS-CoV-2 target in a molecular multi-analyte test, would it be necessary to validate and obtain a pooling claim for the non-COVID influenza or respiratory targets?
QE 5-2: Is there a mechanism to obtain a pooling claim just for the COVID target in a molecular multi-analyte test, such as a labeling restriction or masking other results?

##### Implicit Questions Extraction
QI 5-1: What are the FDA's recommendations or mitigation strategies for pooling validation when focusing only on SARS-CoV-2 in a molecular multi-analyte test?
QI 5-2: If masking the non-COVID analytes in a molecular multi-analyte test is used as a mitigation strategy, would further validation for those analytes still be necessary?
QI 5-3: Is it possible to pool only for SARS-CoV-2 testing in a multi-analyte test while excluding other targets?
QI 5-4: Are there conditions or requirements for masking non-COVID results in a molecular multi-analyte test to focus on pooled SARS-CoV-2 testing?

#### Section 6 of 14
##### Explicit Questions Extraction
QE 6-1: Is it true for antigen tests that if a test is validated for NP swabs, it can also be used for anterior nasal swabs without additional validation?
QE 6-2: If a manufacturer validates their kit for NP swabs, do they also need to include anterior nasal swab testing in the validation for antigen tests?

##### Implicit Questions Extraction
QI 6-1: What is the FDA's position on using anterior nasal swabs for antigen test validation instead of nasopharyngeal swabs?
QI 6-2: Are there specific reasons or advantages for validating antigen tests with anterior nasal swabs or mid-turbinate swabs?
QI 6-3: Can antigen tests validated with anterior nasal swabs be used for self-collection or home use?
QI 6-4: Does the FDA require manufacturers to validate antigen tests for nasopharyngeal swabs if validating for anterior nasal swabs?
QI 6-5: Is it necessary to demonstrate performance differences between nasopharyngeal and anterior nasal swabs for antigen tests?
QI 6-6: How does the FDA recommend validating COVID-19 antigen tests for home use or over-the-counter use?

#### Section 7 of 14
##### Explicit Questions Extraction
QE 7-1: Do you have any updates or current thoughts on the PPA or sensitivity requirements for a breath test for screening COVID?

##### Implicit Questions Extraction
QI 7-1: What population is most appropriate to target for a breath test, symptomatic or asymptomatic?
QI 7-2: Why does the FDA recommend targeting asymptomatic populations specifically for novel breath tests?
QI 7-3: What level of sensitivity is considered relatively high for asymptomatic populations in novel breath tests?
QI 7-4: Why does the FDA require more positive cases for breath tests compared to antigen or molecular tests for asymptomatic screening?
QI 7-5: How can developers demonstrate cross-reactivity testing for breath tests, given the analyte is not a virus?
QI 7-6: What is the FDA's recommended method for conducting cross-reactivity studies for breath tests?
QI 7-7: Is there a required percentage of symptomatic patients to include in cross-reactivity studies for breath tests?
QI 7-8: Can testing a respiratory panel authorized for SARS and other viruses satisfy the cross-reactivity requirement?

#### Section 8 of 14
##### Explicit Questions Extraction
QE 8-1: Does the FDA have a standardized list of hardware requirement categories for a test system that includes a smartphone, such as processor type or camera, or is it up to the test developer to provide and justify their list of requirements?
QE 8-2: Would you recommend reaching out directly for a more detailed conversation about a smartphone-based test system, or should we simply present the data as part of the submission?

##### Implicit Questions Extraction
QI 8-1: What variables or factors should be considered during validation for smartphone-based diagnostic tests, such as lighting, line color, line thickness, or background?
QI 8-2: Does the FDA have prior experience or authorizations for smartphone-based diagnostic test readers?
QI 8-3: What role does the FDA's research branch play in evaluating or supporting the development of technologies like smartphone-based test readers?
QI 8-4: Should test developers focus on testing specific smartphone models or software configurations to ensure accurate validation of results?
QI 8-5: What are the FDA's expectations for defining and validating key parameters in smartphone-based diagnostic systems?

#### Section 9 of 14
##### Explicit Questions Extraction
QE 9-1: Has there been an update on the reference panel testing by the CDC for EUA authorized antigen tests?
QE 9-2: Have CDC officials started reaching out to antigen manufacturers to request samples of the product?
QE 9-3: What is the general status on the reference panel testing process?

##### Implicit Questions Extraction
QI 9-1: What are the alternatives being considered by the FDA if the CDC is unable to conduct reference panel testing as planned?
QI 9-2: Is irradiated SARS-CoV-2 suitable for antigen test developers to use in validating their assays?
QI 9-3: What specific methods does the FDA recommend for inactivating SARS-CoV-2 strains for use in antigen testing?
QI 9-4: Can the BEI-inactivated virus materials be used by developers who lack BSL-3 facilities to perform necessary testing?
QI 9-5: How long does it typically take for BEI to inactivate SARS-CoV-2 and verify its non-infectious status?
QI 9-6: What preliminary data does the FDA have supporting the use of irradiated virus in antigen test validation?
QI 9-7: Are there potential limitations for antigen tests if the virus is treated with radiation?

#### Section 10 of 14
##### Explicit Questions Extraction
QE 10-1: If a BSL-3 facility completes most analytical studies for an antigen test, would the FDA allow the remainder to be completed post-EUA?
QE 10-2: Have antigen test submissions from companies using Chinese OEMs shown a pattern of failing to meet FDA requirements for home use, such as 90% sensitivity?
QE 10-3: Is it possible for a Chinese OEM to obtain EUA for an antigen test?
QE 10-4: How difficult would it be to have three or four OEMs producing the same test for a test developer?

##### Implicit Questions Extraction
QI 10-1: What are the FDA's expectations for testing and verifying the performance of tests at new manufacturing sites?
QI 10-2: Are there specific challenges the FDA has observed in the development or manufacturing of high-quality antigen tests?
QI 10-3: What factors contribute to the lower approval rate for lateral flow serology and antigen tests compared to molecular tests?
QI 10-4: Does the FDA require distinct criteria for the US market versus other global markets regarding antigen tests?

#### Section 11 of 14
##### Explicit Questions Extraction
QE 11-1: Are the UDI G10 requirements for Class II and higher tests applicable right now for an EUA test?

##### Implicit Questions Extraction
QI 11-1: When will the FDA confirm whether UDI G10 requirements are applicable to EUA tests?
QI 11-2: Will the FDA add information about UDI requirements for EUA tests to the Frequently Asked Questions page?

#### Section 12 of 14
##### Explicit Questions Extraction
QE 12-1: What guidance is available for reporting personal and user data for at-home COVID-19 tests using a mobile app?
QE 12-2: Is it necessary to include a mechanism in the app to estimate the prevalence in the consumer's region to provide indications on positive and negative predictive value for the test results?
QE 12-3: Does the FDA consider the prediction of COVID-19 prevalence in the app user's region as a risk mitigation factor for prescription-based COVID-19 tests?

##### Implicit Questions Extraction
QI 12-1: How can an app comply with HIPAA requirements when reporting COVID-19 test results?
QI 12-2: What challenges should developers expect when trying to obtain state and federal authorizations for reporting COVID-19 test results from a mobile app?
QI 12-3: What data connectivity considerations exist for linking a reporting app to state and federal databases?
QI 12-4: Can the FDA provide links to online resources or documents that outline recommendations for reporting COVID-19 test results?
QI 12-5: Is it feasible to use geo-located prevalence data to adjust the interpretation of antigen test results within an app?
QI 12-6: What prerequisites are necessary to implement prevalence-based risk mitigation in a diagnostic app?
QI 12-7: How can prevalence data be integrated into a system in real-time to ensure proper mitigation of risk in test result interpretation?
QI 12-8: Would the FDA accommodate creative or novel mitigation proposals incorporating COVID-19 prevalence data through the pre-EUA or EUA process?

#### Section 13 of 14
##### Explicit Questions Extraction
QE 13-1: Is there any issue with using already distributed antigen tests for our organization's surveillance testing?

##### Implicit Questions Extraction
QI 13-1: What does the FDA consider to be the difference between diagnostic and surveillance testing?
QI 13-2: Does the FDA provide guidelines for conducting surveillance testing with antigen tests?
QI 13-3: Is pooling required for surveillance testing according to the FDA's guidelines?
QI 13-4: Can surveillance testing results be used to directly inform individuals of their infection status?
QI 13-5: What is the FDA's current stance on follow-up testing for individuals in a positive pool from surveillance testing?

#### Section 14 of 14
##### Explicit Questions Extraction
QE 14-1: What are the requirements of a usability study for a molecular point-of-care claim?
QE 14-2: For a point-of-care molecular test, should we include 30 participants in the human usability study as per the guidance?
QE 14-3: What is the scope required for a usability study to support a point-of-care claim?
QE 14-4: Are we required to do an additional usability study beyond the clinical study for a molecular point-of-care test?

##### Implicit Questions Extraction
QI 14-1: What are the expectations for validating point-of-care tests in multiple clinics?
QI 14-2: Do usability studies for point-of-care molecular tests require five to six different operators performing the test?
QI 14-3: Are there differences in user study requirements between point-of-care and home-based (OTC or prescription) molecular tests?
QI 14-4: Should clinical study design for point-of-care tests incorporate usability elements to streamline submission?
